Niger. J. Physiol. Sci. 36 (December 2021): 123 – 147
www.njps.physiologicalsociety.com
https://doi.org/10.54548/njps.v36i2.1
Review Article
Essential Metals in the Brain and the Application of Laser
Ablation-Inductively Coupled Plasma-Mass Spectrometry for
their Detection
Folarin, O.R.1, Olopade F.E.2 and Olopade J.O.3
1
Department of Biomedical Laboratory Science, College of Medicine, University of Ibadan. Ibadan, Nigeria
2
Department of Anatomy, College of Medicine, University of Ibadan. Ibadan, Nigeria
3
Department of Veterinary Anatomy, Faculty of Veterinary Medicine, University of Ibadan. Ibadan, Nigeria
Summary: Metals are natural component of the ecosystem present throughout the layers of atmosphere; their abundant
expression in the brain indicates their importance in the central nervous system (CNS). Within the brain tissue, their
distribution is highly compartmentalized, the pattern of which is determined by their primary roles. Bio-imaging of the brain
to reveal spatial distribution of metals within specific regions has provided a unique understanding of brain biochemistry and
architecture, linking both the structures and the functions through several metal-mediated activities. Bioavailability of
essential trace metal is needed for normal brain function. However, disrupted metal homeostasis can influence several
biochemical pathways in different fields of metabolism and cause characteristic neurological disorders with a typical disease
process usually linked with aberrant metal accumulations. In this review we give a brief overview of roles of key essential
metals (Iron, Copper and Zinc) including their molecular mechanisms and bio-distribution in the brain as well as their
possible involvement in the pathogenesis of related neurodegenerative diseases. In addition, we also reviewed recent
applications of Laser Ablation Inductively Couple Plasma Mass Spectrophotometry (LA-ICP-MS) in the detection of both
toxic and essential metal dyshomeostasis in neuroscience research and other related brain diseases.
Keywords: Metal dyshomeostasis, Bio-imaging, LA-ICP-MS, Neurodegenerative diseases, Essential metals, CNS
©Physiological Society of Nigeria
*Address for correspondence: jkayodeolopade@yahoo.com; +23408023860829
Manuscript received- April 2021; Accepted- November 2021
INTRODUCTION
Metals are found ubiquitously in the environment, they are
present in air, land, water and various parts of the earth crust
(Chen et al., 2016). They form the major parts of the CNS
and their critical role in several pathophysiological
processes has been of keen interest to several researchers
(Flora and Pachauri, 2010). Metals are categorized into
essential and toxic metals based on their biological
functions (Chen et al., 2016). Essential metals include
copper (Cu), zinc (Zn), iron (Fe), manganese (Mn), lithium
(Li), nickel (Ni), chromium (Cr), selenium (Se), and cobalt
(Co). These trace metals are required in an adequate amount
and are the key regulatory factors for many cellular
activities and brain physiological processes (Lee et al.,
2008; Becker et al., 2010; Chen et al., 2016; DeBenedictis
et al., 2020). Although they are needed for normal brain
activities, their deficit or excess through genetic,
environmental or nutritional disposition may be linked with
several neurological diseases. Their quantitative
determination is of growing interest in brain research and
biosciences and is relevant for studying many neurological
diseases (Becker et al., 2007; Becker et al., 2010; Chen et
al., 2016). Out of the aforementioned essential trace metals
found in the brain, Zinc, Iron and Copper are the most
significant players in both neurophysiology and
neuropathology, particularly with regard to aging and
neurodegenerative diseases, they constitute the major
component of various proteins and enzymes essential for
normal brain function and also connected to specialized
brain activities (Que et al., 2008; Prashanth et al., 2015).On
the other hand, toxic metals such as vanadium, arsenic,
cadmium, lead, mercury, uranium and nickel are ubiquitous
in nature, they are found freely in water, food and in green
vegetation (Becker et al., 2007; Pohl et al., 2011;
Tchounwou et al., 2012; Bhat, 2017; Bhat, 2019). Sources
are also through some human activities such as heavy metal
mining, crude oil processing, chemicals and toxic waste
disposal as well as emission from industrial and electricitygenerating (particularly coal-burning) activities (Arruti et
al., 2010; Sträter et al., 2010; Pohl et al., 2011; Iqbal and
Ahmed, 2019).
Toxic metals possess no functional role in human
homeostasis and constitute a risk for most of the chronic
neurodegenerative diseases (they elicit severe damages as
they easily transverse the brain barrier, bind brain tissue to
induce oxidative stress, block aquaporins, interfere with
normal endocrine activities and displace essential cations
such as zinc and magnesium (Chen et al., 2016; Becker et
al., 2010). In addition, toxic metal exposure early in life
pose the risk of lifelong behavioural, intellectual and
physical impairment as well as accelerated brain ageing in
young adults and children (Pohl et al., 2011; CalderónGarcidueñas et al., 2012). Several age-related neurological
disorders are strongly linked with disrupted metal
homeostasis, thus, brain metal content and their spatial
124
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
distribution in the diseased brain is usually obtained and
compared with that of controls. Therefore, besides the
analysis of food, beverages and environmental samples, the
study of elemental distribution in brain and biological
tissues is of great importance (Becker et al., 2008; Becker et
al., 2010). This will give a clue to the overall diagnosis of
individuals with a metal poisoning symptomatology or
dyshomeostasis. It will also inspire newer therapeutic
strategies in the diagnosis and potential treatment of several
metal induced neurological diseases.
Molecular Biology of Trace Metals in The Brain and
Their Roles in Brain Function: Trace metals are
micronutrients usually found in relatively small amount but
highly needed for proper growth and function of a biological
system (Zecca et al., 2004; Anderson et al., 2011). Being
the major part of most vitamins and enzymes, they
participate in key oxidative-reduction reactions that control
several other cellular metabolic activities (Bartzokis et al.,
2007; Que et al., 2008). In the CNS trace metals such as
cobalt, copper, iodine, iron, manganese, molybdenum,
selenium, and zinc combine with specific enzymes to
catalyze several activities involved in various neurological
processes e.g. Iodine is bound to thyrosine, colbat is a
component of vitamin B12 and zinc has a special function
in zinc metalloenzymes (Que et al., 2008). Although, trace
metals are needed for proper brain development, their
balances and transportation within the CNS is essential and
strictly controlled by a complicated barrier system involving
the blood-brain barrier (BBB), choroidal bloodcerebrospinal fluid barrier, blood-cerebrospinal fluid (CSF)
barrier, and even CSF-brain barrier (Takeda et al., 2004;
Strazielle and Ghersi-Egea, 2013; Hladky and Barrand,
2016). Since some essential trace metals need to be obtained
from the environment in adequate amounts to optimize
cellular metabolism, their homeostasis within the brain is
dependent on the control of processes such as absorption,
distribution, biotransformation, and excretion (Zheng and
Monnot 2012; Fu et al., 2014). However, their excess or
deficit as well as impaired homeostatic metabolic
mechanism often generate oxidative stress with deleterious
effects on the neurons and glia resulting in
neurodegeneration and neurological dysfunction (GarzaLombo et al., 2018). For example, low iron content has been
related with brain disabilities such as pediatric stroke,
pseudo-tumor cerebri, and cranial nerve palsy (Yager and
Hartfield, 2002; Rangarajan and D’Souza, 2007), while
aberrant iron, zinc, copper and calcium accumulation was
associated with Alzheimer's disease brain (Leskovjan et al.,
2009, 2011; Li et al., 2017; Grochowski et al.,
2019), highly concentrated iron in neuro-melanin is
implicated in dopaminergic mal-function in Parkinson's
disease (Sian‐Hülsmann et al., 2011; Depboylu et al.,
2007), deficiencies in copper-binding proteins was also
linked with neurological disorders such as Menkes and
Wilson diseases (Squitti et al., 2012; Squitti et al., 2013;
Strausak et al., 2001). The chemical reactivity, spatial
distribution as well as biological functions of each essential
trace element is quite variable within the CNS, iodine for
example is low in content and less distributed, relative to
elements such as iron and selenium which are enormous in
volume and fairly evenly distributed in all regions of the
brain. Others such as copper and zinc are also found to be
highly enriched in some regions and nuclei (Bartzokis et al.,
2007).
Molecular Biology, Bio-Distribution And Roles Of
Copper: Copper is one of the essential transition metals
needed by the brain. It is rated as the third most abundant
trace metal in the CNS; it has an average neural
concentration in order of 0.1 Mm (Linder and HazeghAzam, 1996; Stöckel et al., 1998; Gaggelli et al., 2006). It
is unevenly distributed in different parts of the brain with
higher accumulation in the grey matter when compared with
the white matter (Dobrowolska et al., 2008). Additionally,
high concentration of copper was specifically reported in
some brain regions such as substantia nigra, locus coeruleus,
dentate nucleus, basal ganglia, hippocampus, and
cerebellum (Madsen and Gitlin, 2007; Becker et al., 2007b,
Popescu et al., 2009a, Davies et al., 2013). The highest level
of copper was found in the basal ganglia, while in glia cells,
it was double fold higher in concentration when compared
to that of the neuron, especially at the ventricular regions
(Madsen and Gitlin, 2007; Becker and Salber, 2010).
Transportation of copper within the CNS is highly
dependent on its oxidation state which enables it to be
readily involved in several redox activities (Macreadie,
2008). The reduced form of copper is mostly transported and
is found in higher concentration within the intracellular
environment such as the neurons and glia cells, in contrast
to the oxidized forms which are less in abundance and found
mostly in extracellular spaces such as the blood serum, CSF
and synaptic cleft (Macreadie 2008; Que et al., 2008). In
the peripheral blood, copper ions are usually transported as
free ions which transverses the BBB into the brain
parenchyma from where it is utilized for several redox
activities and subsequently released into the CSF. Choroid
epithelial cells absorb copper from the CSF, and thus
facilitate its clearance from the brain to maintain normal
brain copper balance (Zheng and Monnot, 2012). Effective
cellular copper transportation and homeostatic control is
achieved by binding with specific protein transporters and a
subset of intracellular proteins known as Cu chaperones
which enhances its delivery for specific targets involved in
biochemical activities. Upon entering the cell, the fate of
copper ions includes; (1) entering into Cu-metallothionein
storage pool, (2) incorporation into cytochrome c oxidase in
mitochondria for energy generation (3) incorporation into
cytoplasmic Cu/Zn SOD for antioxidation; and (4)
conveyed to a P-type ATPase in the trans-Golgi network for
secretion (Que et al., 2008; Zheng and Monnot, 2012;
Grochowski et al., 2019). The membrane-associated Cu
transporters include copper transporter-1 (CTR1), DMT1,
and Cu exporter ATPases (ATP7A and ATP7B). The
chaperones include antioxidant protein-1 (ATOX1),
cytochrome oxidase enzyme complex (COX17), and Cu
chaperone for SOD (CCS) (Harris, 2001). Current
scientific research has demonstrated the existence of several
of these protein transporters, in the Blood Brain Barrier
(BBB) and Blood Cerebrospinal Fluid Barrier (BCB) where
they facilitate the entering of copper ions into brain tissue
(Choi and Zheng, 2009).
ATOX1 (formerly HAH1) is a copper chaperone
belonging to a larger family of metallochaperone proteins
that binds copper and convey it in a specific pathway
manner within the CNS. In addition to their intracellular
Essential Metal detection in brain using LA-ICP-MS
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
copper ions delivery, they also play the additional role of
preventing toxicity through removal of unused free copper
ions in the brain. ATOX1 associates with the Cu-ATPases
located in the trans-Golgi network to perform intracellular
copper trafficking and also found widely distributed in the
choroid plexus and brain capillary endothelial cells
(Nishihara et al., 1998; Hamza et al., 2001; Hamza et al.,
2003; Zheng and Monnot, 2012). COX17 is another copper
chaperone widely distributed in the neuronal cells, but its
existence is not yet confirmed in the BBB or BCB. COX17
mediates the delivery of cytosolic copper to cytochrome c
oxidase of mitochondrion for energy metabolism (Kaler,
2011; Hamza and Gitlin, 2002). CCS is a chaperone
required for the incorporation of Cu into Cu–Zn SOD in
mammals for antioxidant defence (Culotta et al., 2006; Que
et al., 2008; Grochowski et al., 2019). Metallothionein (MT)
are cysteine-rich copper binding cytoplasmic proteins that
chelate excess free copper ions due to much larger Cu-MT
binding affinity relative to affinity for other metals such as
zinc (Nishimura et al., 1992; Que et al., 2008; Ba et al.,
2009). MT was reported to be widely expressed in BB and
BCB and plays additional role of regulating intracellular Cu
storage by binding Cu ions at the brain barriers (Que et al.,
2008). ATP7A and ATP7B, variants of P-type ATPases are
also copper chaperones that regulate cellular copper
homeostasis, through the removal of excess copper ions
within the brain cells via the trans-Golgi network secretory
pathway (Zheng and Monnot, 2012). They also regulate the
release of copper ions to cuproenzymes during
neurotransmitter formation and metabolism and mediate
uptake of copper ions into the brain from plasma through the
BBB and CSF- brain barrier system (Grochowski et al.,
2019; Zheng and Monnot, 2012). ATP7B specifically play
essential role in excreting excess copper ions in the biliary
system. While ATP7A is expressed ubiquitously in several
brain regions such as the cerebellum and hippocampus, as
well as the BBB endothelium, ATP7B are found mostly in
the liver cells and in a specific few brain cells such as
Purkinje neurons (Madsen and Gitlin, 2007; Zheng and
Monno,t 2012), However, both ATP7A and ATP7B was
reported to be well expressed in the apical membrane of the
gut enterocytes, choroid plexus ependymocytes and
capillary endothelium (Mercer et al., 2001; Choi and Zheng
2009; Merle et al., 2016). Copper transporter-1 (Ctr-1) is a
representative member of copper transport protein family
that is expressed widely in many tissues including the brain,
specifically within BBB endothelium where they mediate
copper uptake into the brain tissue from plasma (Que et al.,
2008; Madsen and Gitlin, 2007; Zheng and Monnot, 2012).
Their expression is usually upregulated in perinatal copper
deficiency, however, in a situation of high cellular copper
level, Ctr-1 becomes inactive and totally degraded (Madsen
and Gitlin, 2007). Amyloid precursor protein (APP), DMT1 and prion protein (PrP) are other abundant copper
transporter proteins in the brain that are essential for the
uptake and efflux of copper ions, thereby maintaining
normal neural copper homeostasis (Madsen and Gitlin,
2007).
Copper as a redox active nutrient is required in optimal
level to cope with high oxygen capacity and oxidative
metabolism of brain tissue. As a main component or cofactor for various enzymes, it is essential for a series of
protein/enzyme regulated biological functions including
125
energy metabolism involving mitochondrial cytochrome c
oxidase, protection against oxidative damage involving
Cu/Zn superoxide dismutase (SOD1), modulation and
biosynthesis of neuropeptide, regulator of iron metabolism
as well as neurotransmitter and intracellular release of
copper ion from mobile storage during neural activities
(Scheiber and Dringen, 2013; Scheiber et al., 2014;
Kozlowski et al., 2012; Sheykhansari et al., 2018).
Copper dyshomeostasis and neurodegenerative diseases:
Copper is a redox metal that co-ordinates several biological
activities, its accumulation in the brain may be toxic to the
body cells if its homeostatic mechanism is not accurately
regulated (Kozlowski et al., 2012; Emwas et al., 2013).
Failure of well refined copper homeostatic control can lead
to a number of neurodegenerative diseases such as
Parkinson’s disease (PD), Menkes disease, Alzheimer’s
disease (AD), familial amyotrophic lateral sclerosis (fALS),
Prion diseases, and Wilson disease. In addition to this,
higher ability of copper to bind ligands within the cells can
also trigger unregulated cellular reactions leading to severed
cell impairment and death (Kozlowski et al., 2012).
Involvement of copper ion in pathogenesis of
Alzheimer’s disease is attributed to abnormal binding of Cu
ions with APP and the product of its cleavage (β amyloids)
which lead to formation of intermediate metalloproteins
(copper-amyloid complex) that triggers fenton-type reaction
and rapid generation of highly reactive free radical such as
hydroxyl radical (OH-) and hydrogen peroxide (H2O2)
which mediate a number of repeated oxidative stress cycle
that ultimately promote repeated plaque formation with
subsequent accumulation in the brain including the
extracellular fluids (Parthasarathy et al., 2014). In a number
of studies, high level of copper and zinc were seen in the
amyloid plaque and CSF from AD patients (Bolognin et al.,
2011; Huzumi et al., 2011; Cardoso et al., 2013).
Prion disease is another neurodegenerative disorder that has
been linked with copper ion dyshomeostasis, prion proteins
are cell surface copper binding glycoprotein that has six
attachment domains for copper ions (Nadal et al., 2009).
Scientific evidence is available for the possible involvement
of prion proteins in the regulation of brain copper
metabolism including cellular signaling, anti-oxidation and
buffering activities (Walter, 2009; Nadal et al., 2009).
Studies have also revealed that, higher affinity of cellular
form of prion proteins (PrPC) for free Mn2+ ions than Cu2+
ions may facilitate its modification into a typical toxic,
pathological isoform (PrP- Sc), the resultant free unbound
Cu2+ ions may further aggravate the disease pathogenesis
through free radical generation and oxidative damage
(Kozlowski et al., 2010). However, there are discrepancies
in the physiological function of copper in the etiology of
prion protein diseases, and thus makes the phenomenon not
to be completely understood (Kozlowski et al., 2010;
Thakur et al., 2011).
Parkinson’s disease is a debilitating motor disorder
characterized by progressive degeneration of dopaminergic
neurons of the substantia nigra and intracellular deposition
of lewy bodies, a misfolded form of α-synuclein protein
(Paik et al., 1999; Uversky et al., 2001). Fibrillation of αsynuclein into a misfolded form is facilitated by its binding
with several toxic and trace metals in the brain which
promote free radical generation and oxidative stress. Self-
Essential Metal detection in brain using LA-ICP-MS
126
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
oligomerization of alpha synuclein was reported to be
initiated by copper binding in the presence of toxic radicals
such as H2O2 (Paik et al., 1999; Uversky et al., 200). Paik et
al. (1999) also reported copper II induced selfoligomerization of α-synuclein in the presence of coupling
reagents such as dicyclohexylcarbodi-imide. Studies have
reported that oligomer species of α-synuclein requires
association with copper ions to induce neuronal death (Paik
et al., 1999; Wright et al., 2009; Brown, 2009; Wang et al.,
2010).
Familial amyotrophic lateral sclerosis (fALS) is
genetically linked disorder which majorly affects motor
neurons in the primary motor cortex, corticospinal tracts,
brainstem and spinal cord (Rowland et al., 2001; Wijesekera
and Leigh, 2009). fALS is believed to be either caused by
gain of a novel toxic function of the protein or by mutation
of essential gene encoding cytosolic Cu/Zn binding
superoxide dismutase SOD, a metalloprotein that catalyzes
the conversion of toxic superoxide anion radical O- into
hydrogen peroxide (Shibata et al., 2000; Shibata, 2001;
Howland et al., 2002; Valentine et al., 2005), and is
responsible for 20% of the inherited form of the disease
(Deng et al., 1993; Goto et al., 2000).
Menkes and Wilson diseases are genetic disorders
associated with the dysregulation of copper homeostasis
(Llanos and Mercer, 2002; Polishchuk et al., 2019; Hartwig
et al., 2019; Weiskirchen et al., 2019). It is caused by
mutation in the Cu-transporter ATPase7B gene that encodes
a protein responsible for the biliary efflux of copper ions,
(Boaru et al., 2014). ATPase7B are involved in
sequestration of excess Cu into bile, and CSF for
excretion. They also incorporate excess copper into
ceruplasmin apoproteins to avoid systemic toxicity (Boaru
et al., 2014; Merle et al., 2016). Genetically defected
ATPase7B copper (Cu) efflux pump resulted in impaired Cu
excretion and gradual accumulation in the body organs
(liver, brain and kidney) (Merle et al., 2016); excessive
copper overload in the brain and liver ultimately resulted
into clinical manifestation such as liver cancer and severe
psychiatric and neurologic symptoms which are without
specific therapy (Weiskirchen et al., 2019). Menkes disease
is a storage copper disorder characterized by high
accumulation of copper in non-hepatic tissue but deficit in
the liver, the brain and the blood, due to mutation in the
Menke- ATP7A gene encoding for Cu-transport protein,
failure in ATP7A is responsible for the resulting systemic
brain copper deficiency and reduced copper-containing
enzymes (cuproenzyme) activity (Vulpe et al., 1993; Tumer
2013). In Menkes disease various ATP7A mutation induced
deficiency in transportation of copper across the placenta,
blood-brain barrier and gastrointestinal tract (Waggoner
1999; Strausak et al., 2001; Weiskirchen et al., 2019).
Molecular biology, bio-distribution and roles of Zinc in
the brain: Zinc is a trace nutrient needed for normal brain
function and maturation; it is rated as the 2nd most abundant
trace element in the brain (Sensi et al., 2009; Kambe et al.,
2015). It is a structural part of many proteins and co-factor
of more than 300 enzymes involved in numerous cellular
signaling pathways and functions, Zinc is found to be
irregularly distributed in the brain but highly concentrated
in some regions such as amygdala, neocortex, olfactory
bulb, hippocampus, gray matter of the cortex and neurons
(Takeda, 2000; Frederickson et al., 2001). In the brain, zinc
exists in two forms; the most abundant static form (Zn 2+),
constitutes up to 90% of the neuronal zinc and is usually
tightly bound with numerous metalloproteins. The static or
chelatable form plays structural roles in protein as well as
structural and catalytic roles in enzymes; the labile or ionic
form, constituting up to 10% are widely distributed within
the presynaptic vesicles of zinc-dependent glutamatergic
neurons (Que et al., 2008). The glutamate and zincreleasing neuronal system forms the cortical–limbic
associational network that unites limbic and cerebrocortical
functions, and contains a vast number of glutamate- and
zinc-releasing neurons with their cell bodies scattered
within the cerebral cortex and limbic structures
(Frederickson et al., 2001; Kozlowski et al., 2012). During
neuronal activity the co-release of labile zinc at
micromolar level with some classical neurotransmitter
from the glutamatergic presynaptic vesicle resulted
into modulation of their postsynaptic activity, for example
Zn2+ has an inhibitory effect on N-methyl-D-aspartate
(NMDA), GABAA and glycine inotropic receptors but
highly activate α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate (AMPA) glutamate receptors and a specific
metabotropic Zn2+-sensing receptor GPR39 (Smart et al.,
2004; Besser et al., 2009). The neuroprotective effect of zinc
at physiological concentration have been reported, however
deficit concentrations exceeding the physiological level was
found to be highly neurotoxic, effective zinc transportation
and homeostatic control is therefore required, to avoid brain
cytotoxicity and damage (Fukada et al., 2011; Szewczyk,
2013; Maywald et al., 2017). Zinc transportation is usually
mediated by a numerous number of zinc homeostatic
regulatory proteins distributed widely in the brain tissue,
they are classified into three major groups; ZnTs belonging
to a larger family of SLC30 is a membrane bound protein
that excretes cystosolic zinc from the cell or influx zinc ions
from extracellular space into intracellular compartment or
organelles (Huang et al., 2013; Kambe et al., 2015; Portbury
and Adlard, 2017). The second group are the ZIP a member
of zinc and iron-regulatory transporter proteins (SLC39
family) that are widely distributed in the brain and
responsible for trafficking of zinc from the extracellular
space or from intracellular vesicles to the cytoplasm
(Cousins et al., 2006; Kambe et al., 2015). About 10 and 14
variants of ZnTs and ZIP that control zinc transportation in
mammalian system have been identified (Cousins et al.,
2006). The third group is the Metallothioneins (MT), low
molecular weight proteins that have affinity for zinc metals.
Zinc dyshomeostasis and neurodegenerative diseases:
The role of zinc as essential nutrients for normal brain
function is being increasingly appreciated; however, studies
have shown that zinc overdose resulting from defective
homeostasis is linked with the pathophysiology of many
neuropsychiatric diseases (Szewczyk et al., 2013; Portbury
and Adlard, 2017). Clinical conditions such as epilepsy and
stroke are associated with excessive influx of zinc into
neurons that ultimately leads to excitotoxic neuronal death.
On the other hand, zinc deficiency has been implicated to
affect neurogenesis which triggers neuronal apoptosis and
consequently leads to learning and memory impairment
(Frederickson et al., 2005; Szewczyk et al., 2013). Effective
transportation and homeostatic control to maintain
Essential Metal detection in brain using LA-ICP-MS
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
intracellular and extracellular zinc concentration at nontoxic
level is achieved by a number of regulating proteins which
includes membrane Zn2+ transporters proteins (ZnT and
Zip), and metallothioneins (Sensi et al., 2009; Szewczyk et
al., 2013; Portbury and Adlard, 2017). Alteration in any of
these proteins have been implicated in the etiology of ageing
and age related neurodegenerative diseases such as
amyotrophic lateral sclerosis (ALS), Parkinson’s disease
(PD) and Alzheimer’s disease (AD) (Frederickson et al.,
2004; Szewczyk et al., 2013; Portbury and Adlard,
2017). Recently, alteration in ZnT and MT was implicated
in ageing and progression of Alzheimer’s disease (AD) (Yu
et al., 2001; Wong et al., 2013).
Alzheimer’s disease (AD) is one of the age related
neurodegenerative diseases associated with Zinc
dyshomeostasis. It is characterized by extracellular
deposition of amyloid plaques and intracellular
accumulation of Neurofibrillary tangles (NFT), the
pathological hallmarks of the disease (Bolognin et al., 2011;
Portbury and Adlard, 2017). Defective zinc homeostasis
may contribute to pathogenesis of AD by promoting protein
aggregation and deposition (Szewczyk et al., 2013), several
lines of evidences have shown that zinc upregulation to
toxic concentration (above 300 nM) in extracellular fluids
can promote plaque formation in AD (Bush et al., 1994; Ha
et al., 2007; Noy et al., 2008). Amyloid precursor proteins
(APP) are abundantly distributed in the plasma membrane
of neurons, with their functions virtually unknown, however
their proteolytic cleavage yield Aβ peptides. Zinc
availability is essential for APP function and metabolism
especially in the regulation of its formation and processing
(Grilli et al., 1996; Lee et al., 2009), located on the APP
ectodomain is the cysteine-rich regions that constitute the
binding site for Zn ions (Bush et al., 1994b; Que et al.,
2008). The processing of APP also depends on activities of
enzymes secretases (α, β and γ). The common route by
which APP is processed in the brain is through the cleavage
by α-secretase, within the Aβ region, producing sAPP
(soluble amyloid precursor peptide) (Ling et al., 2003).
Aberrant binding of zinc ions to APP may prevent the
activities of α- secretases, to yield non-amyloidogenic
peptide (soluble amyloid precursor peptide); further
reduction in α-secretase activity facilitates the formation of
defective Aβ peptides by its β and γ secretases counterparts
(Wilquet and De, 2004). Several studies have highlighted
the contribution of
zinc dyshomeostasis in amyloid
pathology of AD; a research study using ZnT3 knockout
mice showed reduced vulnerability toward amyloid plaque
deposition (Ritchie et al., 2003), while administration of
copper-zinc chelator clioquinol was shown to prevent or
ameliorate amyloid plaque aggregation in an additional
study (Regland et al., 2001; Ritchie et al., 2003). Oxidative
stress has also been suggested as another risk factor
contributing to AD pathology (Butterfield et al., 2001;
Jomova et al., 2010) ROS such as NO and peroxynitrate or
exogenous oxidant could mediate mobilization of zinc ion
from extracellular metallothioneins (MT) and zinc
transporters (ZnT) which further upregulate intracellular
zinc concentration to toxic level that triggers general tissue
damage such as mitochondrion dysfunction and
further promote ROS formation (Aizenman et al., 2000;
Burdette and Lippard, 2003; Sensi et al., 2003; BossyWetzel et al., 2004). Sensi et al. (2008) indicate ROS
127
mediated Z2+ upregulation in AD neurons expressing mutant
APP, presenilin-1 (PS-1) and tau. Another pathway through
which zinc could be implicated in AD pathology is through
hyperphosphorylation of tau proteins to generate
neurofibrilary tangles another hallmark of AD. Studies have
shown that zinc at micromolar concentration can promote
NFT formation (Bjorkdahl et al., 2005; Pei et al., 2006; Mo
et al., 2009) and the use of appropriate zinc chelator can
effectively block hyperphosphorylation of tau (Sun et al.,
2012).
Amyotrophic lateral sclerosis (ALS) is a chronic
disorder characterized by the selective death of motor
neurons (Rowland and Shneider, 2001). It is both familiar
and sporadic in nature with the sporadic form constituting
about 90% of the cases and 10%, the familiar form
(Portbury and Adlard, 2017). Mutation in the gene encoding
copper, zinc superoxide dismutase (SOD1) is responsible
for about 20% of the inherited form of the disease. Mounting
evidences are available, suggesting the involvement of zinc
dyshomeostasis in the pathogenesis of ALS (Frederickson
et al., 2005). Studies have shown that mutation of SOD
genes result in loss of zinc from its active site and toxic gain
of function in motor neurons (Frederickson et al., 2005;
Roberts et al., 2007). Loss of zinc from SOD mutants has
been reported to triggers peroxynitrate induced protein
nitration, a toxic reaction presumes to contribute to selective
death of motor neurons in ALS disease (Crow et al., 1997).
In another study, deficiency of zinc in SOD mutant was
observed to promote nitric oxide induced motor neuron
degeneration in ALS disease (Estevez et al., 1999). In
addition to SOD mutation, several studies have reported the
involvement of metallothioneins (MTs) and zinc
transporters (ZnTs) in the progression of ALS; a recent
study has discovered downregulation of ZnT3 and ZnT6 in
the spinal cord of ALS patient (Kaneko et al., 2015).
Another study also recorded reduced expression of zinc
metallothionein RNAs in the spinal cord of patient with
sporadic form of ALS (Ishigaki et al., 2002; Hozumi et al.,
2008b). In a study using a mutant SOD transgenic mouse,
deficiency of MT1, MT2 or MT3 was shown to exacerbate
ALS expression (Nagano et al., 2001; Puttaparthi et al.,
2003). All these together have suggested the possible
involvement of zinc dyshomeostasis in ALS disease
pathogenesis.
Parkinson’s disease is a chronic progressive
neurological disease associated with defective motor
system. Clinical symptoms develop gradually over time and
include tremor, rigidity, postural instability, paucity of
movement, behavioural and learning deficit and dementia
which is associated with the late phase of the disease. Zinc
deficiency has been detected in patients presenting with PD
and the efficacy of appropriate zinc supplementation to
reverse zinc shortage in animal model of PD has been
demonstrated (Forsleff et al., 1999; Brewer et al., 2010). In
addition, accumulation of zinc in specific brain regions
associated with PD pathology such as substantia nigra,
lateral putamen and caudate nucleus in patients expressing
PD have been demonstrated (Dexter et al., 1991). Also
Drosophila parkin mutants, a PD disease model expressing
human PD phenotype with deficits such as, severely shorten
life span and locomotor defect due to degenerated flight
muscles were restored back to normal through zinc
supplementation (Saini et al., 2010). Together all these
Essential Metal detection in brain using LA-ICP-MS
128
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
evidences have indicated the contributory role of zinc
dyshomeostasis in the pathogenesis of PD.
Molecular biology, bio-distribution and roles of Iron in
the brain: Iron is the most prevalent transition metal in the
brain (Que et al., 2008; Beard et al., 2009). The brain being
the organ with the highest rate of cellular metabolism
requires iron as a major constituent of enzymes to carry out
the process of oxygen transportation and metabolism
(Cammack et al., 1990). Within the brain, iron is
homogeneously distributed with the highest concentration
found in the basal ganglia, thus suggesting basal ganglia as
the major iron storage and distribution in the brain (Beard et
al., 2009; Anderson and Erikson, 2011). In a cohort study
conducted by Aoki et al. (1989), magnetic resonance
imaging (MRI) of the brains of children and adolescents
confirmed the substantia nigra, caudate nucleus, globus
pallidus and putamen as the brain regions with highest iron
concentration while the concentration remained relatively
low in the cerebellum and cortex. Studies have also
confirmed white matter as the major site of iron
concentration within the brain with maximum influx
occurring during rapid brain growth at the peak of
myelinogenesis (Taylor and Morgan, 1990). Iron is also
widely distributed in all cell types of the CNS including,
microglia, oligodendrocytes, astrocytes and neurons, with
oligodendrocytes having the highest concentration (Que et
al., 2008). In the biological tissue, iron exists in two
common oxidative states namely: +2 (ferrous) and +3
(ferric) oxidation states, other higher redox states are
generated through several enzymatic catalytic cycles
occurring in the cell (Que et al., 2008). With regard to the
brain, iron participates in several neurological activities
which includes involvement in the function and biosynthesis
of neurotransmitters (Youdim, 1990; Loeffler et al., 1995),
myelin formation (Beard et al., 1993; Que et al., 2008;
Anderson and Erikson, 2011), cofactor for a variety of
metalloenzymes and an essential role in neuronal function
(Beard et al., 1993; Anderson and Erikson, 2011). Despite
high need of iron in the brain, only a small quantity, about
5-10% is expected to be used for iron-dependent processes
(Sigel et al., 2006), while the large portion of the unused
(about 33-90%) is stored in ferritin. Due to abundance of
iron in the brain and its high redox activities, tight
homeostatic regulation is required to prevent oxidative
damage to the cells by unlimited iron dependent Fenton
reactions (Beard et al., 1993; Que et al., 2008). To avoid
iron toxicity and deficiency, an elegant homeostatic system
comprising transferrin, transferrin receptors, and ferritin are
in place to ensure effective storage and well-timed release
of iron to the cells. The mechanism of transportation of iron
in the CNS is not fully comprehended, however both the
transferrin-mediated and axoplasmic flow have been
described as the most common pathway of iron into the
neurons and grey matter (Dwork et al., 1990).
Iron initially absorbed from the gastrointestinal tract is
integrated into ferritin and plasma transferrin for systemic
storage and transportation. Influx of iron into the brain
across the blood-brain barrier (BBB) is mediated through a
general pathways involving transferrin (Tf), the transferrin
receptor (TfR) localized on brain endothelial cells. Iron in
oxidized state is incorporated into transferrin (Tf) and bound
with transferrin receptor (TfR) to form TfFe2-TfR complex
that is translocated across the BBB into the brain. Once in
the brain, the influx of iron into the cell occurs through a
few major pathways the choice of which is dependent on the
cell type and brain region involved. Within the brain the
resulting TfFe2-TfR complex is endocytosed into the cell
through clathrin-coated endosomes, which undergoes
acidification to liberate Fe3+ from transferrin, Fe3+ is
further reduced to Fe2+ by an unknown mechanism and
subsequently transported into mitochondria through
mitoferrin by a mechanism mediated by divalent metal
transporter-1 (DMT1), a mitochondrial iron transporter
abundantly expressed in astrocytes. Within the
mitochondrion, transported Fe2+ is utilized for the synthesis
of heme and iron-sulfur clusters, while the remaining left
over is incorporated into ferritin for storage. Other
alternative pathway employed for iron uptake into brain
cells include ferritin and ferritin receptors (FtR) (occurring
in white matter in oligodendrocytes (Hulet et al., 1999;
Hulet et al., 2000) the transferrin / transferrin receptor
pathway (Hulet et al., 2000), lactoferrin mediated pathway
which involves importing of iron into neuromelanin cells
(Zecca et al., 2004) and divalent metal transporter-1
(DMT1) abundantly expressed in astrocytes.
Intracellularly iron homeostatic regulation is controlled
through translational level with iron responsive elements
(IREs) and iron regulatory proteins (IRPs) (Hentze and
Kühn, 1996; Eisenstein, 2000). The nucleotide sequences of
IREs are fully expressed on mRNA. The expression and the
activities of TfR, Ft, and other iron metabolic regulatory
proteins is controlled by IRP/IRE interactions. During
intracellular iron depletion, the cell put up compensatory
action and initiate: binding of IREs of TfR mRNA and Ft
mRNA to IRPs to boost intracellular iron level
by preventing iron degradation and reduce the population
of iron stores in ferritin, while in the case of excess
intracellular
iron,
conformational
alteration
in
IRPs is initiated to prevent IRE binding and increase
ferritin level required for excess iron sequestration or initiate
TfR mRNA degradation to reduce subsequent iron influx
into the cell. Other iron regulatory proteins whose
expression is regulated by the IRP/IRE system include
DMT1 and ferroportin-1 (FPN1) (Abbou and Haile, 2000;
Dunn et al., 2007). FPN1 is an iron regulatory protein that
controls efflux of iron from the cell. It is abundantly
expressed in the brain (Abbou and Haile, 2000; Donovan et
al., 2000; Burdo et al., 2001) and its over expression has
been reported to result in intracellular iron deficiency
(Abbou and Haile, 2000).
Iron dyshomeostasis and neurodegenerative diseases:
Iron is an indispensable metal that is essential for several life
processes and cellular functions, its level rises with age.
Aberrant iron accumulation in the brain due to misregulated homeostasis is a characteristic of several
neurological disorder such as Alzheimer’s disease
(AD) (Que et al., 2008; Li and Reichmann, 2016; Bjørklund
et al., 2019). As a redox active element, iron is involved in
several cellular activities, which if unregulated, may result
in oxidative damage to macromolecule and cellular
dysfunction (Belaidi et al., 2016; Eid et al 2017; Masaldan
et al., 2018), evidences are available in the literature which
show that abnormal iron accumulation in the brain promote
protein aggregation through Fenton- type oxidation of
Essential Metal detection in brain using LA-ICP-MS
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
macromolecules (Zecca et al., 2004; Madsen and Gitlin,
2007; Que et al., 2008).
Parkinson’s disease (PD) is a debilitating disease of the
brain characterized by the accumulation of αsynuclein and degeneration of substantia nigra (SN)
neurons (Que et al., 2008; Li and Reichmann, 2016; CostaMallen et al., 2017; Bjørklund et al., 2019). It affects about
2% of human population globally especially in ages well
above 65 years (De Rijk et al., 1997). Clinical symptoms for
PD include tremor, muscle rigidity, bradykinesia (slow
movements), and deterioration of cognitive functions
(Rinne et al., 2000). Both the genetic and the environmental
factor have been strongly implicated in the etiology of PD,
and several research studies have highlighted the role of
environmental factors in the disease pathogenesis such as
induction of parkinsonism in rats by MPTP (1-methyl-4phenyl-1,2,3,6-tetrahydropyridine) exposure. Exposure to
different environmental toxicant, exposure to toxic metals
(Pb, V, Hg) as well as the essential trace element
dyshomeostasis (iron, copper, manganese, zinc) have also
contributed to the development of PD (Bjørklund et al.,
2019). Evidences are available supporting impaired iron
homeostasis as a function of elevated iron accumulation
observed in PD, studies done on post mortem brain iron
content using MRI and LA-ICP-MS bio-imaging revealed
massive accumulation of iron in the SN of brain tissues
obtained from various forms of PD (Li and Reichmann,
2016; Costa-Mallen et al., 2017; Bjørklund et al., 2019). Invivo measurements of brain iron by magnetic resonance
imaging (MRI) also confirmed the presence of increased
iron deposition in the SN (Wallis et al., 2008; Rossi et al.,
2013). Another study also detected reduction in the level of
ferritin and neuromelanin (iron binding proteins) in the SN
of PD individuals when compared with normal individuals
(Connor et al., 1995; Zecca et al., 2002; Que et al., 2008).
Further studies also found abnormally elevated iron
accumulation in oligodendrocytes, astrocytes, microglia,
and pigmented neurons and in the rim of Lewy bodies in PD
patients. All these evidences confirm the association of
disrupted iron homeostasis with the pathogenesis of PD. So
far, the primary mechanism that is responsible for excessive
iron accumulation in PD is insufficiently defined, however,
disrupted BBB, α-synuclein aggregation, oxidative stress,
mitochondrial dysfunction and iron dyshomeostasis have
been suggested to be involved (Que et al., 2008; Li and
Reichmann, 2016). Moreover, these factors together with
iron accumulation constitute the process leading to neuroinflammation and neuro-degeneration. In PD pathology the
vicious cycle of mitochondrial injury, oxidative stress, iron
dyshomeostasis and neuro-inflammation are closely
interrelated with several other factors in PD (Li and
Reichmann, 2016).
Interactions between excess Fe ions and various
molecules in the brain are implicated in the pathology of PD.
For example, the interaction of electrophilic ferric iron with
dopamine in SN could be a major factor associated with
neurotoxicity and neurodegeneration in PD (Que et al.,
2008; Li and Reichmann, 2016). In the presence of elevated
ferric iron, dopamine interacts with molecular oxygen to
yield quinones and free oxygen radicals (ROS) which
appeared to be toxic to SN cells (Zucca et al., 2014).
Dopamine can be polymerized and oxidized directly to form
a characteristic coloured neuromelanin or its other multiple
129
toxic metabolites (Miyazaki et al., 2008; Zucca et al., 2014).
The free reactive radical (ROS) generated promote protein
carbonylation which subsequently triggers α-synuclein
aggregation and Lewy body formation (Munch et al., 2000).
Excess iron in SN may directly interact with α-synuclein and
catalyse its aggregation into α-synuclein oligomer, while αsynuclein in excess may induce massive iron accumulation,
excessive aggregated α-synuclein
generated
further
exacerbate oxidative stress, mitochondrion impairment and
iron dyshomeostasis (Devi et al., 2008; Que et al., 2008;
Davies et al., 2011; Funke et al., 2013). Another example is
the interaction of excess ferric ion with neuromelanin
pigment, the end product of dopamine metabolism to form
neuromelanin iron complex (NM-Fe3+), which is seen in the
degenerating neurons of the SN of PD patients (Jellinger et
al., 1992; Zecca et al., 1996). Fe3+ stored in degenerating
neurons of SN is released into extracellular environment
where it interacts with microglia and trigger the release of
neurotoxin that mediate neuro-inflammatory cascade. The
release of NM-Fe3+ complex from degenerating neurons
further triggers a cascade of events leading to neuronal death
through microglial activation (Wilms et al., 2003; Zucca et
al., 2014). Disrupted iron homeostasis seen in PD has also
been attributed to mis-regulation of normal brain iron
regulatory system, studies have shown changes in brain iron
level in different forms of PD while the serum iron remain
largely unaltered (Logroscino et al., 1997; Tórsdóttir et al.,
1999; Costa-Mallen et al., 2015; Costa-Mallen et al., 2017).
In addition, increase in the level of ferritin iron saturation as
well as the level of lactoferrin and lactoferrin receptors,
which are the potential source of iron storage in the
brain, were detected in SN of PD patient in comparison with
normal individual (Faucheux et al., 1995; Leveugle et al.,
1996).
Alzheimer’s disease (AD) is another degenerative
disease of the brain strongly linked with dysfunctional iron
homeostasis, and evidences are available showing
association of aberrant iron accumulation with AD
pathology (Connor et al., 1992; Smith et al., 2007; Bulk et
al., 2018; Everett et al., 2018). Amyloid plaque and
neurofibrillary tangles (NFT) which are pathology
hallmarks of the disease were also found with high iron
deposits (Connor et al., 1992). Studies on postmortem brain
from AD patients revealed high iron accumulation
especially in the hippocampus (Connor et al., 1992; Deibel
et al., 1996). In addition to this, iron may also directly
trigger β amyloid formation and aggregation through several
pathway including oxidative stress which is built up in the
cell by the activities of other redox metals (Zn, Cu) and thus
promote oxidation and subsequent crosslinking of β amyloid
species (Huang et al., 1999; Bush et al., 2003; Que et al.,
2008; Jomova et al., 2010). Alteration of iron regulatory
proteins involved in the removal of excess iron from the
brain to prevent iron overload has also been implicated in
promoting iron dyshomeostasis in AD (Connor et al., 1993;
Guerreiro et al., 2015; Wan et al., 2011). This is further
confirmed in an analysis on iron transportation and storage
which revealed reduced iron mobilization in AD compared
to normal individuals (Connor, 2018), the level of Divalent
Metal Transporter 1 (DMT1) an iron importer is increased,
while the level of ferroportin 1 (FPN1) and Ceruloplasmin
(CP) cellular iron exporters were relatively low in AD brain
(Connor et al., 1993; Wan et al., 2011; Guerreiro et al.,
Essential Metal detection in brain using LA-ICP-MS
130
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
2015). Intracellular iron distribution and accumulation may
also affect the formation and processing of amyloid
precursor protein (APP). The expression of iron responsive
element (IRE) identified on the 5’ end of APP mRNA, is
suggestive of the role of iron in the regulation of APP
formation and processing (Connor et al., 1993; Que et al.,
2008; Ward et al., 2014), for example excess iron
accumulation, has been reported to promote APP formation
(Bodovitz et al., 1995). In addition, iron responsive element
(IRE) on APP mRNA is involved in the translational
processing of amyloid precursor protein (APP). Excess iron
overload may trigger aberrant binding of iron responsive
element and subsequently promote β amyloids formation
and aggregation (Bodovitz et al., 1995; Rogers et al., 2002;
Crichton et al., 2008; Caldwell et al., 2013). The common
route of APP processing is non amyloidogenic pathway that
involves proteolytic cleavage of APP by α and γ secretases
to yield a neuroprotective extracellular soluble A β peptide,
(Ling et al., 2003) and prevent the formation of β-amyloids
however, in AD, APP cleavage by β and γ secreatases
produced amyloidogenic fragments of β amyloid which
subsequently aggregate to form plaque (Bodovitz et al.,
1995; Silvestri. and Camaschella, 2008; Ward et al., 2014).
Furthermore, the processing of APP is regulated by iron
through furin (Hwang et al., 2006). Furin is a calciumdependent proconvertase, produced in the endoplasmic
reticulum (ER) and largely involves in promoting αsecretases cleavage of amyloid protein precursor (APP) to
yield the sAPP neuroprotective form. However, excessive
iron accumulation has been reported to decrease furin
expression and enhanced β amyloids accumulation and
aggregation in the brain (Bodovitz et al., 1995; Silvestri and
Camaschella, 2008). Additionally, accumulated iron in
neurofibrillary tangles (NFT) can mediate tau
phosphorylation and aggregation (Yamamoto et al., 2002;
Lovell et al., 2004; Chan and Shea, 2006; Castellani et al.,
2012).
Amyotrophic lateral sclerosis (ALS) is another
neurodegenerative disorder associated with aberrant iron
trafficking and distribution, it is a debilitating progressive
CNS disease characterized by gradual degeneration of
motor neurons in the cerebral cortex, brain stem and the
spinal cord. ALS affects mostly growing population with
global incidence of up to 1/100,000 (Carrı̀ et al., 2003;
Goodall et al., 2008). ALS is categorized into familiar and
the sporadic form, but both with similar clinical symptoms
and pathological process (Portbury and Adlard, 2017;
Sheykhansari et al., 2018). Iron as a cofactor is essential for
various enzymatic catalyzed reactions in the brain
(Hametner et al., 2013). A balanced brain iron homeostasis
is essential to prevent deleterious effect on cell functions
due to high accumulation, mis-regulation of iron may
promote neuro-inflammation, mitochondrial impairment
and oxidative stress (Carrı̀ et al., 2003; Goodall et al., 2008;
Hadzhieva et al., 2013; Tokuda et al., 2016), although the
involvement of iron in the etiology of ALS is unclearly
defined, however, redox capacity of iron to generate ROS
has been proposed as one of the factors that initiate ALS
pathology (Hametner et al., 2013). Moreover, mutation of
the gene encoding copper-zinc dismutase (SOD), that
constitutes about 20% of the familiar form of the disease has
also been implicated in the pathogenesis of the disease
(Yoshida et al., 2010). In normal conditions SOD is
responsible for the catalytic conversion of toxic superoxide
anion radical Ointo hydrogen peroxide through
dismutation reactions (Shibata et al., 2000; Shibata, 2001;
Howland et al., 2002;Valentine et al., 2005). SOD
impairment result to reduction in dismutation activities and
toxic accumulation of superoxide radicals that subsequently
generates oxidative stress. Studies have demonstrated the
ability of excess superoxide radicals O- to remove iron from
iron bearing proteins such as ferritin (Jeong et al., 2009;
Jomova et al., 2010), the extracted iron is further
incorporated into Fenton and Haber Weiss reactions to
generate more free radicals such as OH- and O2- which are
toxic to brain cells (Wang et al., 2004; Jeong et al., 2009;
Jomova et al., 2011). Furthermore, mutation of the genes
controlling appropriate cellular iron homeostasis has been
proposed as one of the predisposing factors to ALS
(Zamboni et al., 2005). Mutation in Hfe with the associated
hemochromatosis and decrease in Cu/Zn SOD1 activities
have been implicated in ALS (Zamboni et al., 2005;
Gemmati et al., 2006; Singh et al., 2010; Gemmati et al.,
2012). There are several
indications showing the
involvement of aberrant iron homeostasis
in the
pathophysiology of ALS; assessment of iron state levels in
ALS patient revealed high ferritin level associated with
worsened muscle degeneration and shortened patients’
survival (Goodall et al., 2008; Veyrat-Durebex et al., 2014;
Nadjar, et al., 2012; Ikeda et al., 2012), abnormal iron
accumulation has also been detected in the spinal cord of
ALS patients (Yasui et al., 1993; Ince et al., 1994; Kasarskis
et al., 1995; Markesbery et al., 1995), Furthermore, high
iron concentration has been reported in the CSF of ALS
patients (Hozumi et al., 2011). Using animal model of ALS,
motor neuron degeneration due to aberrant iron deposition
was reported in SOD transgenic mice (Winkler et al., 2014),
The use of appriopriate iron chelator therapy to alleviate
aberrant iron accumulation in a G93A-SOD1 murine model
of ALS, resulted in neuroprotection and long life survival
(Kupershmidt et al., 2009; Wang et al., 2011).
Multiple Sclerosis (MS) is a type of demyelinating CNS
disorder associated with mis-regulated iron homeostasis. It
is characterized by general disruption of iron regulatory
mechanism
controlled
by
oligodendrocytes.
Oligodendrocytes are responsible for maintenance and
myelin production, alteration in this regulatory process
could lead to aberrant iron accumulation within the cell that
triggers oxidative damage (Beard et al., 1993; Sheykhansari
et al., 2018). Aberrant iron accumulation in the brain and
associated oxidative stress is a component of MS pathology
(Ferreira et al., 2017; Iranmanesh et al., 2013; Hametner et
al., 2013). Studies have reported alteration in the normal
cellular pattern of iron and transferrin due to cellular iron
dyshomeostasis (Craelius et al., 1982; LeVine et al., 1997).
Age related increase in iron accumulation was also seen in
the white matter of MS subject (Hametner et al., 2013),
Moreover, extensive glial degeneration including iron rich
oligodendrocytes and myelin has been reported in MS
lesion, the free iron liberated further exacerbates oxidative
stress and leads to neurodegeneration (Uttara et al., 2009;
Khare et al., 2014; Raymond et al., 2017), on the other
hand, reduced iron accumulation with upregulated oxidative
stress has been found in MS disease (Visconti et al., 2005;
Crichton et al., 2008). Several studies have used
experimental animal models to investigate the
Essential Metal detection in brain using LA-ICP-MS
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
pathophysiology of MS and their report have been
documented, destructive blood brain barrier with excessive
iron accumulation have been reported in animal model of
experimental allergic encephalomyelitis (EAE) which is one
of the clinical condition of MS (Forge et al., 1998). In
addition to this, endogenous administration of appropriate
antioxidant has proven to reverse the clinical and
pathological symptoms linked with experimental
autoimmune neuritis in animal model of autoimmune
demyelination (Hartung et al., 1988).
Methods of metal detection in the brain: Elemental or
molecular mapping in biological tissue is of growing
interest in different areas of biomedical research (Sussulini
and Berker, 2015; Wu et al., 2011), in brain research it is
mostly used for the detection of spatial element distribution
and quantification in the brain. It is relevant in the study of
neurodegenerative diseases (Hutchinson et al., 2005; Hare
et al., 2009; Wang et al., 2010; Becker et al., 2010; Hare et
al., 2010; Hare et al., 2014), proteomics (Wind et al., 2003;
Becker et al., 2004; Feng et al., 2015) as well as aging and
oncogenic research (Becker, 2005; Zoriy et al., 2006; Salber
et al., 2007; Seuma et al., 2008; Fu et al., 2015). It also
detects changes in metal distribution, homeostasis and
contents within brain anatomical structures (Hare et al.,
2017; Becker et al., 2012; Hare et al., 2012).
Presently, there are several analytical techniques
available for detecting metals in biological system for the
purpose of medical investigations, these include nonphotometric techniques such as histochemical techniques
(Wang et al., 2010; Hare et al., 2016), fluorescent method
(Majumdar et al., 2012; Hare et al., 2015) and
autoradiography (Wang et al., 2010; Becker and Salber,
2010); photometric methods such as flame photometry
(Meloni et al., 2007; Elseweidy et al., 2008) and Atomic
absorption spectroscopy (AAS) (Andrási et al., 1999;
Grochowski
et al., 2019)
other surface analytical
techniques include; X-ray spectroscopic techniques (e.g. Xray photoelectron spectroscopy (XPS)( Briggs and Grant,
2012),
scanning electron microscopy with energy
dispersive X-ray analysis (SEM-EDX) (Lohrke et al.,
2017;Pánik et al., 2018), proton-induced X-ray emission
(PIXE) (Carmona et al., 2008; Nakazato et al., 2008), and
imaging mass spectrometry such as secondary ion mass
spectrometry (SIMS) (Chandra et al., 2016), and MALDIMS (matrix assisted laser desorption/ionization mass
spectrometry) (Seeley et al., 2011). However, these methods
have a number of limitations such as non-multi-elemental
capability, poor detection limits, poor lateral resolution,
lower sensitivity for trace analysis and non-availability of
quantification
procedure
when
compared
with spectrometry based method such as Laser ablation inductively coupled plasma - mass spectrometry (LA-ICPMS) a modern powerful micro-analytical technique with
relatively lower matrix effect, high sensitivity, low detection
limit and easy quantification and preparative procedure
(Hattendorf et al., 2003; Hare et al., 2010). LA-ICP-MS
imaging is a modern method applicable for measuring most
of the biological relevant metals and their tissue
concentration. The major goal of this review is to highlight
the role of some essential metals in the brain and recent
applications of LA-ICP-MS imaging in neuroscience,
including brain diseases.
131
Mechanism of LA-ICP-MS: LA-ICP-MS is the most
sensitive and widely used technique for in situ analysis of
metals in cross sections of biological tissue (Becker and
Jakubowski, 2009). It is of significant diagnostic importance
in brain research, where it allows for the detection of
absolute concentration and micro spatial and regional
distribution of elements (metals, non-metals and metalloids)
within the affected brain tissue. It is also essential for
measuring the relative concentration of element within a
large number of metals and metalloids (Mokgalaka and
Gardea-Torresdey, 2006). A classical Laser ablation system
is made up of three key components namely; (A) A high
energy ultraviolet laser beam, (B) easily adjustable ablation
stage, and (C) a detection system comprising of inductively
coupled plasma mass spectrophotometer (ICP-MS). The
detection system is of varied types depending on the type of
mass analyzer used. However, the most widely used is the
quadrupole (Q) based type consisting of a quadrupole mass
filter (Potter 2008) with exceptional quality of high
sensitivity and less design complexity when compared with
the other types such as time of flight (TOF) and double –
focusing sector-field (SF). A laser stage consists of a lens,
an ablation chamber or cell, and adjustable platform to
which is attached an optical microscope equipped with a
charged coupled device (CCD) camera from where the cell
can be effectively monitored and the material of interest
concisely visualized. The mechanism of LA-ICP-MS
involves the use of quadrupole (Q) or double-focusing
sector field (SF) based mass spectrophotometer coupled
with ultraviolet laser beam to vaporize materials from the
surface of biological sample. A thin sliced section mounted
on a glass slide is obtained and fixed into a sample holder
located in a closed ablation chamber or cell. A high energy
laser beam is focused unto the area of interest within the
section, to generate ablated particulates which are
transported in a continuous flow of inert carrier gas such as
argon or helium into the inductively coupled plasma (ICP).
With the extremely high thermal temperature and pressure
of the ICP, the particles, through electromagnetic induction
dissociated into ions, which was further extracted and
directed into a high vacuum mass analyzer, from where ions
are separated into different ones based on their mass - to charge ratios (m/z). Finally, highly sensitive detection and
quantification of the transmitted ions take place (Plates.1a
and1b), (Durrant and Ward 2005; Mokgalaka and GardeaTorresdey, 2006; Weiskirchen et al., 2019).
LA-ICP-MS Bio-imaging of normal brain : LA-ICP-MS
metal bio-imaging is a unique technique that has provided a
new insight in the study of several pathophysiological
processes in brain research. Hare et al. (2016) used LA-ICPMS bio-imaging to produce a three-dimensional atlas
showing the distribution of Zinc (Zn), Copper (Cu) and Iron
(Fe) by using aligned quantified images of these metals
obtained from cerebrum and brainstem sections of a mouse
brain. This atlas has thus contributed to the better
understanding of these essential elements in the brain and
further clarifies their function in neurobiology. Becker et al.
(2005) also employed LA-ICP-MS imaging to produce
spatial distribution of trace elements such as Zn and Cu in
different layers of human hippocampus.
Essential Metal detection in brain using LA-ICP-MS
132
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
Plate 1 (a and b): Experimental workflow of bioimaging of elements in a brain section leading to a quantitative image:
(Adapted from Weiskirchen et al., 2019).
In several research experiments, LA-ICP-MS techniques
have been adopted to produce standard analytical methods
required for data calibration, mostly used in twodimensional mapping and quantitative assessment of
essential trace elements and metals in sections of brain
tissue (Becker et al., 2003; Becker et al., 2005; Zoriy et al.,
2006; Pickhardt et al., 2006). In another follow up study,
LA-ICP-MS was employed to reproduce series of
quantitative data and images of Zn, Cu and Pb distribution
in a numbers of measurements on adjacent sections and
several other representative brain regions such as insula,
central cortex and hippocampus from rat brain
(Dobrowolska et al., 2008)
LA-ICP-MS Bio-imaging in Aging study: Metal
dyshomeostasis or mis-regulation play essential role in brain
aging and neurodegenerative disorders, in the context of
ageing, complimentary potential of LA-ICP-MS with
immunohistochemistry and autoradiography was used to
study age related changes in copper distribution and the
activities of cytoplasmic Cu-SOD in the brain of young (2months), (7-9 months) and aged mouse (14-months). The
analysis showed a progressive depletion of copper
concentration, noticeable in the striatum and ventral cortex
in the aged brain relative to the young brains, the regions
with reduced Cu concentration also corresponded to the
brain regions with reduced cytoplasmic Cu-SOD contents in
the aged mouse. They concluded that decreased Cu content
and SOD level may contribute to vulnerability of the aged
brain to oxidative damage and neurodegeneration (Wang et
al., 2010). In an additional study LA-ICP-MS bioimaging
was employed to study the relative distribution of metals
(Zn and Cu) in the brain of young (2-months) and old (14months) mice. The analysis revealed massive accumulation
of iron in the substantial nigra, the thalamus and the
hippocampal CA 1 region of the older brain when compared
to the young brain, while the zinc concentration largely
appeared constant. This indicates that cerebral iron
accumulation with age may contribute to age related
neurodegeneration since iron catalyzes the formation of
ROS; zinc enrichment observed in hippocampal CA3 of the
young mice indicated the role of zinc in synaptic
transmission (Becker et al., 2010).
Application of LA-ICP-MS in detecting brain metal
dyshomeostasis
Bioavailability of essential trace metal is needed for normal
brain function. However, abnormal distribution can
influence several biochemical pathways in different fields
of metabolism and cause characteristic neurological
diseases (Hare et al., 2017). Involvement of metals in
several neurophysiological and neuropathological events
has prompted the study of their bio-distribution In most
neurodegenerative disorders, the disease process is strongly
linked with abnormal metal accumulations, with several
evidences correlating aberrant metal deposition and
neurodegeneration (Frederickson et al., 2004; Szewczyk et
al., 2013; Portbury and Adlard, 2017). Metal overload or
deficiency sometimes may result from usage of metal
containing drugs such as lithium compounds or cisplatin as
a cytostatic drug against some neurological conditions like
depression and epilepsy or depletion of metal from therapy
to reduce oxidative stress (e.g. in brain after stroke).
Quantitative metal bio-imaging is therefore essential for the
determination of proper brain function and prevention of
certain neurological diseases. This field has therefore
provided a unique understanding of brain biochemical
architecture linking neuroanatomy, metal mediated
processes, changes in metal homeostasis and disease
formation (Hare et al., 2010; Grochowski et al., 2019).
In a study conducted by Boaru et al. (2014), (Plate .2)
LA-ICP-MS was used to investigate cerebral metal
accumulation in the brains of 10-24 months old ATP7B
deficient mice, (animal model of experimental Wilson
disease) and age matched wild types. Brain sections
obtained from the respective animals were comparatively
assessed for the multi-elemental distribution of Na, P, Mn,
Fe, Cu and Zn. The analysis revealed insignificant
difference in the level of Na and P, however, there was an
Essential Metal detection in brain using LA-ICP-MS
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
increased accumulation of Cu throughout the brain
parenchyma but reduced deposition in the periventricular
region, noticeable from 11 months of age. Also observed
was upregulation of Zn concentration in brain regions with
copper enrichment while Fe and Mn concentration remained
relatively constant. Excessive Cu accumulation in
specialized brain area of the ATP7B null mice is indicative
of cognitive impairment and the deposition may be due to
differential regional affinity to Cu within the brain. The
reduced copper accumulation in the perivascular region is in
line with the view that the perivascular region is an efflux
compartment with low copper contents due to active
transportation of Cu into CSF.
In another experiment, Matusch et al. (2010), studied
multi-elemental distribution in the brain of mice subchronically intoxicated with MPTTP as a model for
Parkinson’s disease, 2 h, 7 d and 28 d post treatments,
respective animals were sacrificed and subjected to
investigation. The result showed massive depletion of Cu at
the periventricular zone and fascia dentate at 2 h, 7 d. A
recovery effect was observed at 28d post injury, indicated
133
by increase in Cu concentration in affected brain regions.
Also observed was an increase in Fe concentration in
interpeduncular nucleus, but not in the substantia nigra,
while the level of Zn and Mn were similar to that of the
control. However, the level of C, P, and S. remained
relatively unchanged at all the time points of treatment. This
result confirmed the differential Cu and Fe regulation as
well as their roles in Parkinson’s disease.
Uerling et al. (2018) used LA-ICP-MS imaging to detect
beneficial effect of adeno-associated virus (AAV) gene
therapy to correct Cu dyshomeostasis using a mouse model
of Wilson’ disease (ATP7B transgenic mouse and untreated
litter mates). After 14 weeks of treatment with AAV-AATco-miATP7B therapeutic agent, animals were sacrificed and
together with the untreated litter mates were subjected to
investigation. The result revealed marked reduction in the
level of Cu in some brain regions including the cerebellar
cortex, cerebellar white tract, corpus callosum, 3rd and 4th
ventricles, and basal ganglia of the treated transgenic mice
when compared with the untreated litter mates.
Plate 2:
Comparative assessment of Age-dependent cerebral copper accumulation (10-24 months) in Atp7b deficient mice and agematched wild type as demonstrated by LA-ICP-MS. (Boaru et al., 2014).
Essential Metal detection in brain using LA-ICP-MS
134
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
Also observed was an unaltered content and distribution of
other elements such as the Fe, Zn, Mn and Mg. The study
suggested AAV gene therapy as an effective therapy for the
treatment of cerebral copper overload in Wilson disease
A further advance of application of LA-ICP-MS in the
study of neurodegenerative diseases was seen in a research
conducted by Hutchinson et al. (2005) who employed the
combination of LA-ICP-MS imaging and metal
immunolabelling for the detection of β-amyloid distribution
in the brain of aged TASTPM transgenic mice (model for
Alzheimer) previously tagged with metal (europium)
labeled secondary antibodies. The study detected a
correlation between the β-amyloid deposits and the trace
element content in the brain, this has provided a new insight
into the study of metal tagged antibodies for imaging protein
distribution one of such is seen in a study to detect neuronal
susceptibility to pathological changes observed in
Parkinsonism. In the study the effect of 6-hydroxydopamine
(6-OHDA) neurotoxin on iron level and dopamine
distribution is investigated in a wild-type C57BL/6 mouse
by using antibodies previously tagged with gold particles
(Hare et al., 2014; Ayton et al., 2015).
Another innovative application of LA-ICP-MS is
employed in the identification of metals complexed with
proteins (metalloproteins) such as phosphoproteins. The
combination of LA-ICP-MS technique with proteome
analysis through
advanced
biomolecular
mass
spectrometry techniques such as electrospray ionization
mass spectrometry (ESI-MS) or Matrix-assisted laser
desorption/ionization- mass spectrometry (MALDI) has
provided a new opportunity for the identification of the
detailed structure of metals bound to proteins (metal
protein complexes) as well as detection of protein
modification associated with several pathophysiological
processes (Becker et al., 2010). An example of such is
employed in the study of protein expression in animal model
of Parkinson’s disease unilaterally injected with 6hydroxydopamine, the study revealed accelerated protein
acetylation with changes
in the striatum protein
concentration in dopamine depleted animal when compared
with the controls (Pierson et al., 2004). It is also useful in
the identification of Zn-containing protein such as ATP
synthase b-chain identification- in an Alzheimer’s brain
sample (Becker et al., 2006). In another interesting
application by the Julich group, pulse from LA-ICP-MS was
used for the identification of protein containing Cu, Zn and
Fe in human brain tissue (Becker et al., 2005).
LA-ICP-MS Bio-imaging in toxic metal study; LA-ICPMS imaging has also proven to be useful in toxicological
study; toxic metals have no functional role in normal brain
homeostasis but gradually accumulate in the brain tissue to
elicit severe damage leading to chronic degenerative
diseases. Lead (Pb) and other divalent cations have been
shown to be involved in the damage of calcium- channel
proteins which affect neuronal axons and synaptic release of
neuro-transmitter (Marchetti, 2003), Pb and Mn have also
been implicated in amyloid plaque aggregation
(Yegambaram et al., 2015). The knowledge of toxic metal
distribution in the brain is essential in both health and
medical research where it provide relevant information
needed for the study of pathophysiology and potential
therapeutic treatment, In a recent study LA-ICP-
MS imaging was used to show the distribution of
Lead (Pb) and Uranium (U) in human glioblastoma
multiform brain tumour (Zoriy et al., 2006), Berker et al.
(2008) also used laser imaging to study the distribution of
Uranium and Neodymium in post mortem rat brain
tissue previously treated with these metals . The study
showed high affinity of Uranium and neodymium for white
matter fibres in contrast to its low binding with the grey
matter as well as higher binding of these metals to the
striatum than the cortex. This result is suggestive of
myelinotoxic effect of these metals on the white tract and
striatum neurons.
A time-course study (Plate 3) also used LA-ICP-MS
imaging to study the distribution of vanadium metal a neurotoxicant in the brain of mice following chronic exposure.
The mass spectrometric analysis revealed gradual influx and
accumulation of vanadium metal in several brain regions
with an affinity for the olfactory bulb, brain stem and
cerebellum and progressive clearance from the brain after
withdrawal from the initial exposure. However, the
molecular pathway involved in its clearance is unknown and
needs to be further investigated. The author concluded that
the brain regions with higher vanadium deposition
correspond to the regions where distinct pathologies have
been earlier reported in the literature (Folarin et al., 2017).
LA-ICP-MS bio-imaging in Neurodegenerative diseases
and brain lesions: The use of LA-ICP-MS imaging
techniques has been employed in the study of metal and
elemental dyshomeostasis, diseases pathogenesis and the
potential treatment of metal associated neurodegenerative
diseases such as Alzheimer’s, Parkinson’s and Wilson’s
diseases (Berker et al., 2010). In an attempt to provide a
novel approach for the assessment of white and grey matter
iron accumulation in Alzheimer’s diseases, a pilot study was
conducted using LA-ICP-MS for the comparative analysis
of white and grey matter iron level in an AD brain and
control subject. The study detected intrusion of iron into
grey matter of Alzheimer’s brain when compared with the
control. Upregulation of iron level observed in grey matter
of the AD brain may be indicative of dysregulated iron
homeostasis in vulnerable brain region or inflammatory
response to chronic neurodegeneration (Hare et al., 2016).
LA-ICP-MS bio imaging techniques has a wide application
in the study for detecting metal dyshomeostasis in brain
lesions. In 2005, Becker and colleagues first conducted
brain tumour study by using LA-ICP-MS for quantitative
imaging and spatial distribution of copper, zinc,
phosphorus and sulfur in the brain of rat (F344 Fisher rat)
injected with F98 giloblastoma cells; the study
demonstrated an association between the selected metals
and the brain tumour growth. In another experiment by
Becker and Salber, (2010), LA-ICP-MS bio-imaging was
combined
with
immuno-histochemical
and
autoradiographic techniques to study elemental distribution
and response of several brain cells to brain thrombosis
induced by intense light, using a rat model for stroke. Result
revealed massive accumulation of metals (iron, zinc and
copper) at the thrombotic lesion as well as reactive gliosis
and active neurogenesis at the region surrounding the lesion
site.
Essential Metal detection in brain using LA-ICP-MS
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
135
Plate 3:
Laser ablation-inductively coupled plasma-mass spectrometry (LA–ICP–MS) revealed the regional distribution and
clearance of vanadium metal from mouse brain after chronic exposure and withdrawal from the initial exposure. (Folarin et
al., 2017).
A follow up study was also conducted by Zoriy et al. (2006)
to examine the level of Zn, Pb and U in human glioblastoma
Multiform brain sections. This study employed the
complementary potential of LA-ICP-MS brain imaging and
autoradiography imaging technique. Additional study by
Becker et al. (2005) on small-sized brain tumors, also
detected mark depletions of Cu and Zn around the tumor
area indicating the pathophysiological role of these element
in the tumour growth. Further study on comparative imaging
of P, S, Fe, Cu, Zn and C was conducted by Zoriy et al.
(2007) on thin sections of rat brain tumour, the analysis
detected the relationship between the tumour boundaries
and the regional elemental concentration and distribution.
LA-ICP-MS Bio-imaging in other neurological diseases:
Application of LA-ICP-MS bio-imaging is also extended to
the study of non neurodegenerative disorders. In an
experiment using a mouse model of hypoxia, LA-ICP-MS
imaging revealed massive accumulation of cobalt in the
exposed brains when compared with the control, the
elevated cobalt concentration strongly correlated with
endoplasmic reticulum stress, myelin loss, axonal injury as
well as vitamin B12 enrichment of the brain (Veasey et al.,
2013). Also using mouse model of traumatic brain injury
LA-ICP-MS imaging of mouse brain subjected to a
controlled cortical impact revealed immediate increase in
the level of iron, copper and zinc which was extended
till 28-days post injury (Portbury et al., 2016). In another
experiment, using animal model of post-traumatic stress
disorder, changes in the zinc concentration and
dyshomeostasis were detected using LA-ICP-MS bioimaging. The result showed massive accumulation of Zn in
the hippocampus and dentate gyrus of the stress exposed
brains relative to the control, stress induced zinc
accumulation in the hippocampus could be responsible for
the physiological and behavioral deficit observed in this
disorder (Sela et al., 2017). LA-ICP-MS imaging of metals
in the spinal cord has provided a new insight in the study of
pathogenesis and development of target drugs for treating
motor disorders such as amyotrophic lateral sclerosis
(Robert et al., 2014).
Conclusions and Perspectives: Over the years, LA-ICPMS bio-imaging technique has gained global recognition
and has been consistently employed in different areas of
brain research due to its numerous outstanding features
when compared with other metal bio-imaging methods. In
addition, large list of recent references cited in this review
has confirmed the wide application of LA-ICP-MS in
several metal bio-imaging researches. Despite its wide use,
LA-ICP-MS technique still has a major limitation with
respect to calibration, which prevents it from being a front
line analytical technique for achieving fast, precise and
sensitive metal quantification. The following are the
concluding remarks:
1. Sample preparation is a fundamental issue that must be
highly considered when designing new experiments.
Appropriate protocol must be put in place to prevent
leaching of metal ions from brain sections that may
likely occur during tissue storage and preparation
Essential Metal detection in brain using LA-ICP-MS
136
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
2. Formalin fixation a crucial process in any histochemical
staining protocol usually results in chemical alteration as
well as marked redistribution of trace element and metals
in cut tissue section. This change may alter accurate
interpretation of imaging data. Further study is needed to
evaluate the likely effect of sample preparation on metal
distribution; minimal sample handling is also
recommended to avoid the chance of chemical alteration
in the brain tissue.
3. Preparation of appropriate biological standard for matrix
analysis and better understanding of fractionation and
matrix effect is required for effective LA- ICP-MS bioimaging analysis.
4. Comparative analysis of imaging data obtained from
LA-ICP-MS technique and other metal bio- imaging
method such as a synchrotron-based X-ray fluorescence
microscopy (XFM) could improve data accuracy.
5. The study of cellular organelles and their biochemical
processes could be enhanced by using higher spatial
resolution instrument such as laser microdissection
inductively coupled plasma mass spectrophotometry
(LMD ICP-MS).
6. Complimentary potential of LA-ICP-MS bio-imaging
techniques with other established biomedical imaging
techniques such as magnetic resonance imaging (MRI)
and metallomics has allowed for identification,
quantification and better knowledge of the essential role
of metalloproteins in health and in the pathophysiology
of several neurological diseases.
REFERENCES
Abboud, S., & Haile, D. J. (2000). A novel mammalian
iron-regulated protein involved in intracellular iron
metabolism. Journal of Biological Chemistry, 275(26),
19906-19912.
Aizenman, E., Stout, A. K., Hartnett, K. A., Dineley, K. E.,
McLaughlin, B., & Reynolds, I. J. (2000). Induction of
neuronal apoptosis by thiol oxidation: putative role of
intracellular
zinc
release. Journal
of
neurochemistry, 75(5), 1878-1888.
An, W. L., Bjorkdahl, C., Liu, R., Cowburn, R. F., Winblad,
B., & Pei, J. J. (2005). Mechanism of zinc‐induced
phosphorylation of p70 S6 kinase and glycogen synthase
kinase 3β in SH‐SY5Y neuroblastoma cells. Journal of
neurochemistry, 92(5), 1104-1115.
Anderson, J. G., & Erikson, K. M. (2011). The importance
of trace elements for neurological function. In Handbook
of behavior, food and nutrition (pp. 423-439). Springer,
New York, NY.
Andrási, E., Igaz, S., Szoboszlai, N., Farkas, É., & Ajtony,
Z. (1999). Several methods to determine heavy metals in
the human brain. Spectrochimica Acta Part B: Atomic
Spectroscopy, 54(5), 819-825.
Aoki, S., Okada, Y., Nishimura, K., Barkovich, A. J., Kjos,
B. O., Brasch, R. C., & Norman, D. (1989). Normal
deposition of brain iron in childhood and adolescence:
MR imaging at 1.5 T. Radiology, 172(2), 381-385.
Arruti, A., Fernández-Olmo, I., & Irabien, Á. (2010).
Evaluation of the contribution of local sources to trace
metals levels in urban PM2. 5 and PM10 in the Cantabria
region (Northern Spain). Journal of Environmental
Monitoring, 12(7), 1451-1458.
Aschner, M., & Aschner, J. L. (1990). Manganese transport
across the blood-brain barrier: relationship to iron
homeostasis. Brain research bulletin, 24(6), 857-860.
Ayton, S., Lei, P., Hare, D. J., Duce, J. A., George, J. L.,
Adlard, P. A., ... & Bush, A. I. (2015). Parkinson's disease
iron deposition caused by nitric oxide-induced loss of βamyloid
precursor
protein. Journal
of
Neuroscience, 35(8), 3591-3597.
Bartzokis, G., Tishler, T. A., Lu, P. H., Villablanca, P.,
Altshuler, L. L., Carter, M., ... & Mintz, J. (2007). Brain
ferritin iron may influence age-and gender-related risks of
neurodegeneration. Neurobiology of aging, 28(3), 414423.
Beard, J. L., Connor, J. R., & Jones, B. C. (1993). Iron in
the brain. Nutrition reviews, 51(6), 157-170.
Becker, J. S., & Salber, D. (2010). New mass spectrometric
tools in brain research. TrAC Trends in Analytical
Chemistry, 29(9), 966-979.
Becker, J. S., & Jakubowski, N. (2009). The synergy of
elemental and biomolecular mass spectrometry: new
analytical strategies in life sciences. Chemical Society
Reviews, 38(7), 1969-1983.
Becker, J. S., & Jakubowski, N. (2009). The synergy of
elemental and biomolecular mass spectrometry: new
analytical strategies in life sciences. Chemical Society
Reviews, 38(7), 1969-1983.
Becker, J. S., Boulyga, S. F., Becker, J. S., Pickhardt, C.,
Damoc, E., &Przybylski, M. (2003). Structural
identification
and
quantification
of
protein
phosphorylations after gel electrophoretic separation
using Fourier transform ion cyclotron resonance mass
spectrometry and laser ablation inductively coupled
plasma mass spectrometry. International journal of mass
spectrometry, 228(2-3), 985-997.
Becker, J. S., Gorbunoff, A., Zoriy, M., Izmer, A., &
Kayser, M. (2006). Evidence of near-field laser ablation
inductively coupled plasma mass spectrometry (NF-LAICP-MS) at nanometre scale for elemental and isotopic
analysis on gels and biological samples. Journal of
analytical atomic spectrometry, 21(1), 19-25.
Becker, J. S., Kumtabtim, U., Wu, B., Steinacker, P., Otto,
M., & Matusch, A. (2012). Mass spectrometry imaging
(MSI) of metals in mouse spinal cord by laser ablation
ICP-MS. Metallomics, 4(3), 284-288.
Becker, J. S., Matusch, A., Depboylu, C., Dobrowolska, J.,
& Zoriy, M. V. (2007). Quantitative imaging of selenium,
copper, and zinc in thin sections of biological tissues
(Slugs− Genus Arion) measured by laser ablation
inductively
coupled
plasma
mass
spectrometry. Analytical chemistry, 79(16), 6074-6080.
Becker, J. S., Zoriy, M. V., Dehnhardt, M., Pickhardt, C., &
Zilles, K. (2005). Copper, zinc, phosphorus and sulfur
distribution in thin section of rat brain tissues measured
by laser ablation inductively coupled plasma mass
spectrometry: possibility for small-size tumor
analysis. Journal
of
analytical
atomic
spectrometry, 20(9), 912-917.
Becker, J. S., Zoriy, M., Becker, J. S., Pickhardt, C., &
Przybylski, M. (2004). Determination of phosphorus and
metals in human brain proteins after isolation by gel
electrophoresis by laser ablation inductively coupled
plasma source mass spectrometry. Journal of Analytical
Atomic Spectrometry, 19(1), 149-152.
Essential Metal detection in brain using LA-ICP-MS
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
Belaidi, A. A., & Bush, A. I. (2016). Iron neurochemistry in
Alzheimer's disease and Parkinson's disease: targets for
therapeutics. Journal of neurochemistry, 139, 179-197.
Besser, L., Chorin, E., Sekler, I., Silverman, W. F., Atkin,
S., Russell, J. T., & Hershfinkel, M. (2009). Synaptically
released zinc triggers metabotropic signaling via a zincsensing receptor in the hippocampus. Journal of
Neuroscience, 29(9), 2890-2901.
Bhat, S. A. (2019). Heavy metal toxicity and their harmful
effects on living organisms–a review. International
Journal of Medical Science And Diagnosis
Research, 3(1).
Bhat, S. A., Hassan, T., Majid, S., Ashraf, R., & Kuchy, S.
(2017). Environmental Pollution as Causative Agent for
Cancer-A Review. Cancer Clin. Res. Rep, 1(3).
Björkdahl, C., Sjögren, M. J., Winblad, B., & Pei, J. J.
(2005). Zinc induces neurofilament phosphorylation
independent
of
p70
S6
kinase
in
N2a
cells. Neuroreport, 16(6), 591-595.
Bjørklund, G., Hofer, T., Nurchi, V. M., & Aaseth, J.
(2019). Iron and other metals in the pathogenesis of
Parkinson's disease: Toxic effects and possible
detoxification. Journal of inorganic biochemistry, 199,
110717.
Boaru, S. G., Merle, U., Uerlings, R., Zimmermann, A.,
Weiskirchen, S., Matusch, A., ... & Weiskirchen, R.
(2014). Simultaneous monitoring of cerebral metal
accumulation in an experimental model of Wilson’s
disease by laser ablation inductively coupled plasma mass
spectrometry. BMC neuroscience, 15(1), 1-14.
Bodovitz, S., Falduto, M. T., Frail, D. E., & Klein, W. L.
(1995). Iron levels modulate α‐secretase cleavage of
amyloid
precursor
protein. Journal
of
neurochemistry, 64(1), 307-315.
Bogdanov, M., Brown Jr, R. H., Matson, W., Smart, R.,
Hayden, D., O’Donnell, H., ... & Cudkowicz, M. (2000).
Increased oxidative damage to DNA in ALS
patients. Free Radical Biology and Medicine, 29(7), 652658.
Bolognin, S., Messori, L., Drago, D., Gabbiani, C.,
Cendron, L., & Zatta, P. (2011). Aluminum, copper, iron
and zinc differentially alter amyloid-Aβ1–42 aggregation
and toxicity. The international journal of biochemistry &
cell biology, 43(6), 877-885.
Bossy-Wetzel, E., Talantova, M. V., Lee, W. D., Schölzke,
M. N., Harrop, A., Mathews, E., ... & Lipton, S. A. (2004).
Crosstalk between nitric oxide and zinc pathways to
neuronal cell death involving mitochondrial dysfunction
and p38-activated K+ channels. Neuron, 41(3), 351-365.
Brewer, G. J., Kanzer, S. H., Zimmerman, E. A., Molho, E.
S., Celmins, D. F., Heckman, S. M., & Dick, R. (2010).
Subclinical zinc deficiency in Alzheimer’s disease and
Parkinson’s disease. American Journal of Alzheimer's
Disease & Other Dementias®, 25(7), 572-575.
Briggs, D., & Grant, J. T. (Eds.). (2012). Surface analysis
by Auger and X-ray photoelectron spectroscopy.
SurfaceSpectra.
Brown, D. R. (2009). Metal binding to alpha-synuclein
peptides and its contribution to toxicity. Biochemical and
biophysical research communications, 380(2), 377-381.
Bulk, M., Abdelmoula, W. M., Nabuurs, R. J., van der
Graaf, L. M., Mulders, C. W., Mulder, A. A., ... & van der
Weerd, L. (2018). Postmortem MRI and histology
137
demonstrate differential iron accumulation and cortical
myelin organization in early-and late-onset Alzheimer's
disease. Neurobiology of aging, 62, 231-242.
Burdette, S. C., & Lippard, S. J. (2003). Meeting of the
minds: metalloneurochemistry. Proceedings of the
National Academy of Sciences, 100(7), 3605-3610.
Burdo, J. R., Menzies, S. L., Simpson, I. A., Garrick, L. M.,
Garrick, M. D., Dolan, K. G., ... & Connor, J. R. (2001).
Distribution of divalent metal transporter 1 and metal
transport protein 1 in the normal and Belgrade rat. Journal
of neuroscience research, 66(6), 1198-1207.
Bush, A. I., Masters, C. L., & Tanzi, R. E. (2003). Copper,
β-amyloid, and Alzheimer's disease: tapping a sensitive
connection. Proceedings of the National Academy of
Sciences, 100(20), 11193-11194.
Bush, A. I., Pettingell Jr, W. H., Paradis, M. D., & Tanzi, R.
E. (1994). Modulation of A beta adhesiveness and
secretase site cleavage by zinc. Journal of Biological
Chemistry, 269(16), 12152-12158.
Bush, A. I., Pettingell, W. H., Multhaup, G., d Paradis, M.,
Vonsattel, J. P., Gusella, J. F., ... & Tanzi, R. E. (1994).
Rapid induction of Alzheimer A beta amyloid formation
by zinc. Science, 265(5177), 1464-1467.
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A.
(2001). Evidence of oxidative damage in Alzheimer's
disease brain: central role for amyloid β-peptide. Trends
in molecular medicine, 7(12), 548-554.
Calderón-Garcidueñas, L., Kavanaugh, M., Block, M.,
D'Angiulli, A., Delgado-Chávez, R., Torres-Jardón, R., ...
&
Diaz,
P.
(2012).
Neuroinflammation,
hyperphosphorylated tau, diffuse amyloid plaques, and
down-regulation of the cellular prion protein in air
pollution exposed children and young adults. Journal of
Alzheimer's disease, 28(1), 93-107.
Caldwell, J. H., Klevanski, M., Saar, M., & Müller, U. C.
(2013). Roles of the amyloid precursor protein family in
the peripheral nervous system. Mechanisms of
development, 130(6-8), 433-446.
Cammack, R., Wrigglesworth, J. M., & Baum, H. (1990).
Iron-dependent enzymes in mammalian systems. In Iron
transport and storage (p. 17). CRC Press, Boca Raton.
Cardoso, B. R., Cominetti, C., & Cozzolino, S. M. F. (2013).
Importance and management of micronutrient
deficiencies in patients with Alzheimer’s disease. Clinical
Interventions in Aging, 8, 531.
Carmona, A., Deves, G., & Ortega, R. (2008). Quantitative
micro-analysis of metal ions in subcellular compartments
of cultured dopaminergic cells by combination of three
ion beam techniques. Analytical and bioanalytical
chemistry, 390(6), 1585-1594.
Carrı,̀ M. T., Ferri, A., Cozzolino, M., Calabrese, L., &
Rotilio, G. (2003). Neurodegeneration in amyotrophic
lateral sclerosis: the role of oxidative stress and altered
homeostasis of metals. Brain research bulletin, 61(4),
365-374.
Castellani, R. J., Moreira, P. I., Perry, G., & Zhu, X. (2012).
The role of iron as a mediator of oxidative stress in
Alzheimer disease. Biofactors, 38(2), 133-138.
Chan, A., & Shea, T. B. (2006). Dietary and geneticallyinduced oxidative stress alter tau phosphorylation:
influence
of
folate
and
apolipoprotein
E
deficiency. Journal of Alzheimer's Disease, 9(4), 399405.
Essential Metal detection in brain using LA-ICP-MS
138
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
Chandra, S., Parker, D. J., Barth, R. F., & Pannullo, S. C.
(2016). Quantitative imaging of magnesium distribution
at single-cell resolution in brain tumors and infiltrating
tumor cells with secondary ion mass spectrometry
(SIMS). Journal of neuro-oncology, 127(1), 33-41.
Chen, P., Miah, M. R., & Aschner, M. (2016). Metals and
neurodegeneration. F1000Research, 5.
Choi, B. S., & Zheng, W. (2009). Copper transport to the
brain by the blood-brain barrier and blood-CSF
barrier. Brain research, 1248, 14-21.
Connor, J. R. (2018). Proteins of iron regulation in the brain
in Alzheimer's disease. In Iron and human disease (pp.
365-394). CRC press.
Connor, J. R., Boeshore, K. L., Benkovic, S. A., & Menzies,
S. L. (1994). Isoforms of ferritin have a specific cellular
distribution in the brain. Journal of neuroscience
research, 37(4), 461-465.
Connor, J. R., Snyder, B. S., Arosio, P., Loeffler, D. A., &
LeWitt, P. (1995). A quantitative analysis of isoferritins
in select regions of aged, parkinsonian, and Alzheimer's
diseased brains. Journal of neurochemistry, 65(2), 717724.
Connor, J. R., Snyder, B. S., Beard, J. L., Fine, R. E., &
Mufson, E. J. (1992). Regional distribution of iron and
iron‐regulatory proteins in the brain in aging and
Alzheimer's
disease. Journal
of
neuroscience
research, 31(2), 327-335.
Connor, J. R., Tucker, P., Johnson, M., & Snyder, B. (1993).
Ceruloplasmin levels in the human superior temporal
gyrus in aging and Alzheimer's disease. Neuroscience
letters, 159(1-2), 88-90.
Costa-Mallen, P., Gatenby, C., Friend, S., Maravilla, K. R.,
Hu, S. C., Cain, K. C., ... & Anzai, Y. (2017). Brain iron
concentrations in regions of interest and relation with
serum iron levels in Parkinson disease. Journal of the
neurological sciences, 378, 38-44.
Costa-Mallen, P., Zabetian, C. P., Agarwal, P., Hu, S. C.,
Yearout, D., Samii, A., ... & Checkoway, H. (2015).
Haptoglobin phenotype modifies serum iron levels and
the effect of smoking on Parkinson disease
risk. Parkinsonism & related disorders, 21(9), 1087-1092.
Cousins, R. J., Liuzzi, J. P., & Lichten, L. A. (2006).
Mammalian
zinc
transport,
trafficking,
and
signals. Journal of Biological Chemistry, 281(34), 2408524089.
Craelius, W., Migdal, M. W., Luessenhop, C. P., Sugar, A.,
& Mihalakis, I. (1982). Iron deposits surrounding
multiple sclerosis plaques. Archives of pathology &
laboratory medicine, 106(8), 397-399.
Crichton, R. R., Dexter, D. T., & Ward, R. J. (2008). Metal
based neurodegenerative diseases—from molecular
mechanisms to therapeutic strategies. Coordination
Chemistry Reviews, 252(10-11), 1189-1199.
Crow, J. P., Sampson, J. B., Zhuang, Y., Thompson, J. A.,
& Beckman, J. S. (1997). Decreased zinc affinity of
amyotrophic lateral sclerosis‐associated superoxide
dismutase mutants leads to enhanced catalysis of tyrosine
nitration
by
peroxynitrite. Journal
of
neurochemistry, 69(5), 1936-1944.
Culotta, V. C., Yang, M., & O'Halloran, T. V. (2006).
Activation of superoxide dismutases: putting the metal to
the pedal. Biochimica et Biophysica Acta (BBA)Molecular Cell Research, 1763(7), 747-758.
Davies, K. M., Hare, D. J., Bohic, S., James, S. A., Billings,
J. L., Finkelstein, D. I., ... & Double, K. L. (2015).
Comparative study of metal quantification in neurological
tissue using laser ablation-inductively coupled plasmamass spectrometry imaging and X-ray fluorescence
microscopy. Analytical chemistry, 87(13), 6639-6645.
Davies, K. M., Hare, D. J., Cottam, V., Chen, N., Hilgers,
L., Halliday, G., ... & Double, K. L. (2013). Localization
of copper and copper transporters in the human
brain. Metallomics, 5(1), 43-51.
Davies, P., Moualla, D., & Brown, D. R. (2011). Alphasynuclein is a cellular ferrireductase. PloS one, 6(1),
e15814..
De Rijk, M. D., Tzourio, C., Breteler, M. M., Dartigues, J.
F., Amaducci, L., Lopez-Pousa, S., ... & Rocca, W. A.
(1997). Prevalence of parkinsonism and Parkinson's
disease in Europe: the EUROPARKINSON Collaborative
Study. European Community Concerted Action on the
Epidemiology of Parkinson's disease. Journal of
Neurology, Neurosurgery & Psychiatry, 62(1), 10-15.
DeBenedictis, C. A., Raab, A., Ducie, E., Howley, S.,
Feldmann, J., & Grabrucker, A. M. (2020).
Concentrations of Essential Trace Metals in the Brain of
Animal
Species—A
Comparative
Study. Brain
sciences, 10(7), 460.
Deibel, M. A., Ehmann, W. D., & Markesbery, W. R.
(1996). Copper, iron, and zinc imbalances in severely
degenerated brain regions in Alzheimer's disease:
possible relation to oxidative stress. Journal of the
neurological sciences, 143(1-2), 137-142.
Deng, H. X., Hentati, A., Tainer, J. A., Iqbal, Z., Cayabyab,
A., Hung, W. Y., ... & Roos, R. P. (1993). Amyotrophic
lateral sclerosis and structural defects in Cu, Zn
superoxide dismutase. Science, 261(5124), 1047-1051.
Depboylu, C., Matusch, A., Tribl, F., Zoriy, M., Michel, P.
P., Riederer, P., ... & Höglinger, G. U. (2007). Glia
protects
neurons
against
extracellular
human
neuromelanin. Neurodegenerative Diseases, 4(2-3), 218226.
Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N.
G., & Anandatheerthavarada, H. K. (2008).
Mitochondrial import and accumulation of α-synuclein
impair complex I in human dopaminergic neuronal
cultures and Parkinson disease brain. Journal of
Biological Chemistry, 283(14), 9089-9100.
Dexter, D. T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells,
F. R., Daniel, S. E., ... & Marsden, C. D. (1991).
Alterations in the levels of iron, ferritin and other trace
metals in Parkinson's disease and other neurodegenerative
diseases affecting the basal ganglia. Brain, 114(4), 19531975.
Dobrowolska, J., Dehnhardt, M., Matusch, A., Zoriy, M.,
Palomero-Gallagher, N., Koscielniak, P., ... & Becker, J.
S. (2008). Quantitative imaging of zinc, copper and lead
in three distinct regions of the human brain by laser
ablation
inductively
coupled
plasma
mass
spectrometry. Talanta, 74(4), 717-723.
Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S.
J., Moynihan, J., ... & Zon, L. I. (2000). Positional cloning
of zebrafish ferroportin1 identifies a conserved vertebrate
iron exporter. Nature, 403(6771), 776-781.
Essential Metal detection in brain using LA-ICP-MS
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
Dunn, L. L., Rahmanto, Y. S., & Richardson, D. R. (2007).
Iron uptake and metabolism in the new
millennium. Trends in cell biology, 17(2), 93-100.
Durrant, S. F., & Ward, N. I. (2005). Recent biological and
environmental applications of laser ablation inductively
coupled plasma mass spectrometry (LA-ICPMS). Journal of Analytical Atomic Spectrometry, 20(9),
821-829.
Dwork, A. J., Lawler, G., Zybert, P. A., Durkin, M., Osman,
M., Willson, N., & Barkai, A. I. (1990). An
autoradiographic study of the uptake and distribution of
iron by the brain of the young rat. Brain Research, 518(12), 31-39.
Eid, R., Arab, N. T., & Greenwood, M. T. (2017). Iron
mediated toxicity and programmed cell death: A review
and a re-examination of existing paradigms. Biochimica
et
Biophysica
Acta
(BBA)-Molecular
Cell
Research, 1864(2), 399-430.
Eisenstein, R. S. (2000). Iron regulatory proteins and the
molecular
control
of
mammalian
iron
metabolism. Annual review of nutrition, 20(1), 627-662.
Elseweidy, M. M., & Abd El-Baky, A. E. (2008). Effect of
dietary iron overload in rat brain: oxidative stress,
neurotransmitter level and serum metal ion in relation to
neurodegenerative disorders.
Emwas, A. H. M., Al‐Talla, Z. A., Guo, X., Al‐Ghamdi, S.,
& Al‐Masri, H. T. (2013). Utilizing NMR and EPR
spectroscopy to probe the role of copper in prion
diseases. Magnetic Resonance in Chemistry, 51(5), 255268.
Estévez, A. G., Crow, J. P., Sampson, J. B., Reiter, C.,
Zhuang, Y., Richardson, G. J., ... & Beckman, J. S.
(1999). Induction of Nitric Oxide--Dependent Apoptosis
in Motor Neurons by Zinc-Deficient Superoxide
Dismutase. Science, 286(5449), 2498-2500.
Everett, J., Collingwood, J. F., Tjendana-Tjhin, V., Brooks,
J., Lermyte, F., Plascencia-Villa, G., ... & Telling, N. D.
(2018). Nanoscale synchrotron X-ray speciation of iron
and calcium compounds in amyloid plaque cores from
Alzheimer's disease subjects. Nanoscale, 10(25), 1178211796.
Faucheux, B. A., Nillesse, N., Damier, P., Spik, G., MouattPrigent, A., Pierce, A., ... & Agid, Y. (1995). Expression
of lactoferrin receptors is increased in the mesencephalon
of patients with Parkinson disease. Proceedings of the
National Academy of Sciences, 92(21), 9603-9607.
Feng, T. Y., Yang, Z. K., Zheng, J. W., Xie, Y., Li, D. W.,
Murugan, S. B., ... & Li, H. Y. (2015). Examination of
metabolic responses to phosphorus limitation via
proteomic analyses in the marine diatom Phaeodactylum
tricornutum. Scientific Reports, 5(1), 1-10.
Ferrante, R. J., Browne, S. E., Shinobu, L. A., Bowling, A.
C., Baik, M. J., MacGarvey, U., ... & Beal, M. F. (1997).
Evidence of increased oxidative damage in both sporadic
and familial amyotrophic lateral sclerosis. Journal of
neurochemistry, 69(5), 2064-2074.
Ferrante, R. J., Browne, S. E., Shinobu, L. A., Bowling, A.
C., Baik, M. J., MacGarvey, U., ... & Beal, M. F. (1997).
Evidence of increased oxidative damage in both sporadic
and familial amyotrophic lateral sclerosis. Journal of
neurochemistry, 69(5), 2064-2074.
Ferreira, K. P. Z., Oliveira, S. R., Kallaur, A. P., KaimenMaciel, D. R., Lozovoy, M. A. B., de Almeida, E. R. D.,
139
... & Simão, A. N. C. (2017). Disease progression and
oxidative stress are associated with higher serum ferritin
levels in patients with multiple sclerosis. Journal of the
neurological sciences, 373, 236-241.
Flora, S. J., & Pachauri, V. (2010). Chelation in metal
intoxication. International journal of environmental
research and public health, 7(7), 2745-2788.
Folarin, O. R., Snyder, A. M., Peters, D. G., Olopade, F.,
Connor, J. R., & Olopade, J. O. (2017). Brain metal
distribution and neuro-inflammatory profiles after
chronic vanadium administration and withdrawal in
mice. Frontiers in neuroanatomy, 11, 58.
Forge, J. K., Pedchenko, T. V., & Le Vine, S. M. (1998).
Iron deposits in the central nervous system of SJL mice
with experimental allergic encephalomyelitis. Life
sciences, 63(25), 2271-2284.
Forsleff, L., Schauss, A. G., Bier, I. D., & Stuart, S. (1999).
Evidence of functional zinc deficiency in Parkinson's
disease. The Journal of Alternative and Complementary
Medicine, 5(1), 57-64.
Frederickson CJ, Bush AI (2001) Synaptically released
zinc: physiological functions and pathological effects.
Biometals 14(3-4):353-366.
Frederickson, C. J., Koh, J. Y., & Bush, A. I. (2005). The
neurobiology of zinc in health and disease. Nature
Reviews Neuroscience, 6(6), 449-462.
Frederickson, C. J., Maret, W., & Cuajungco, M. P. (2004).
Zinc and excitotoxic brain injury: a new model. The
Neuroscientist, 10(1), 18-25.
Fu, S., Jiang, W., & Zheng, W. (2015). Age-dependent
increase of brain copper levels and expressions of copper
regulatory proteins in the subventricular zone and choroid
plexus. Frontiers in molecular neuroscience, 8, 22.
Fu, X., Zeng, A., Zheng, W., & Du, Y. (2014). Upregulation
of zinc transporter 2 in the blood–CSF barrier following
lead
exposure. Experimental
Biology
and
Medicine, 239(2), 202-212.
Fukada, T., Yamasaki, S., Nishida, K., Murakami, M., &
Hirano, T. (2011). Zinc homeostasis and signaling in
health and diseases. JBIC Journal of Biological Inorganic
Chemistry, 16(7), 1123-1134.
Funke, C., Schneider, S. A., Berg, D., & Kell, D. B. (2013).
Genetics and iron in the systems biology of Parkinson’s
disease and some related disorders. Neurochemistry
international, 62(5), 637-652.
Gaggelli, E., Kozlowski, H., Valensin, D., & Valensin, G.
(2006). Copper homeostasis and neurodegenerative
disorders (Alzheimer's, prion, and Parkinson's diseases
and
amyotrophic
lateral
sclerosis). Chemical
reviews, 106(6), 1995-2044.
Garza-Lombó, C., Posadas, Y., Quintanar, L., Gonsebatt,
M. E., & Franco, R. (2018). Neurotoxicity linked to
dysfunctional metal ion homeostasis and xenobiotic metal
exposure:
redox
signaling
and
oxidative
stress. Antioxidants & redox signaling, 28(18), 16691703.
Gemmati, D., Tognazzo, S., Catozzi, L., Federici, F., De
Palma, M., Gianesini, S., ... & Zamboni, P. (2006).
Influence of gene polymorphisms in ulcer healing process
after superficial venous surgery. Journal of vascular
surgery, 44(3), 554-562.
Gemmati, D., Zeri, G., Orioli, E., De Gaetano, F. E., Salvi,
F., Bartolomei, I., ... & Zamboni, P. (2012).
Essential Metal detection in brain using LA-ICP-MS
140
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
Polymorphisms in the genes coding for iron binding and
transporting proteins are associated with disability,
severity, and early progression in multiple
sclerosis. BMC medical genetics, 13(1), 1-13.
Goodall, E. F., Haque, M. S., & Morrison, K. E. (2008).
Increased serum ferritin levels in amyotrophic lateral
sclerosis (ALS) patients. Journal of neurology, 255(11),
1652-1656.
Goto, J. J., Zhu, H., Sanchez, R. J., Nersissian, A., Gralla,
E. B., Valentine, J. S., & Cabelli, D. E. (2000). Loss of in
vitro metal ion binding specificity in mutant copper-zinc
superoxide dismutases associated with familial
amyotrophic lateral sclerosis. Journal of Biological
Chemistry, 275(2), 1007-1014.
Grilli, M., Goffi, F., Memo, M., & Spano, P. (1996).
Interleukin-1β and glutamate activate the NF-κB/Rel
binding site from the regulatory region of the amyloid
precursor protein gene in primary neuronal
cultures. Journal of Biological Chemistry, 271(25),
15002-15007.
Grochowski, C., Blicharska, E., Krukow, P., Jonak, K.,
Maciejewski, M., Szczepanek, D., ... & Maciejewski, R.
(2019). Analysis of trace elements in human brain: its
aim, methods, and concentration levels. Frontiers in
chemistry, 7, 115.
Grochowski, C., Blicharska, E., Krukow, P., Jonak, K.,
Maciejewski, M., Szczepanek, D., ... & Maciejewski, R.
(2019). Analysis of trace elements in human brain: its
aim, methods, and concentration levels. Frontiers in
chemistry, 7, 115.
Guerreiro, C., Silva, B., Crespo, Â. C., Marques, L., Costa,
S., Timóteo, Â., ... & Costa, L. (2015). Decrease in APP
and CP mRNA expression supports impairment of iron
export in Alzheimer's disease patients. Biochimica et
Biophysica
Acta
(BBA)-Molecular
Basis
of
Disease, 1852(10), 2116-2122.
Ha, C., Ryu, J., & Park, C. B. (2007). Metal ions
differentially influence the aggregation and deposition of
Alzheimer's
β-amyloid
on
a
solid
template. Biochemistry, 46(20), 6118-6125.
Hadzhieva, M., Kirches, E., Wilisch-Neumann, A., Pachow,
D., Wallesch, M., Schoenfeld, P., ... & Mawrin, C. (2013).
Dysregulation of iron protein expression in the G93A
model
of
amyotrophic
lateral
sclerosis. Neuroscience, 230, 94-101.
Hametner, S., Wimmer, I., Haider, L., Pfeifenbring, S.,
Brück, W., & Lassmann, H. (2013). Iron and
neurodegeneration in the multiple sclerosis brain. Annals
of neurology, 74(6), 848-861.
Hamza, I., & Gitlin, J. D. (2002). Copper chaperones for
cytochrome c oxidase and human disease. Journal of
bioenergetics and biomembranes, 34(5), 381-388.
Hamza, I., Faisst, A., Prohaska, J., Chen, J., Gruss, P., &
Gitlin, J. D. (2001). The metallochaperone Atox1 plays a
critical role in perinatal copper homeostasis. Proceedings
of the National Academy of Sciences, 98(12), 6848-6852.
Hamza, I., Prohaska, J., & Gitlin, J. D. (2003). Essential role
for Atox1 in the copper-mediated intracellular trafficking
of the Menkes ATPase. Proceedings of the National
Academy of Sciences, 100(3), 1215-1220.
Hare, D. J., George, J. L., Grimm, R., Wilkins, S., Adlard,
P. A., Cherny, R. A., ... & Doble, P. (2010). Threedimensional elemental bio-imaging of Fe, Zn, Cu, Mn and
P in a 6-hydroxydopamine lesioned mouse
brain. Metallomics, 2(11), 745-753.
Hare, D. J., Kysenius, K., Paul, B., Knauer, B., Hutchinson,
R. W., O'Connor, C., ... & Doble, P. A. (2017). Imaging
metals in brain tissue by laser ablation-inductively
coupled
plasma-mass
spectrometry
(LA-ICPMS). Journal of visualized experiments: JoVE, (119).
Hare, D. J., Lee, J. K., Beavis, A. D., van Gramberg, A.,
George, J., Adlard, P. A., ... & Doble, P. A. (2012). Threedimensional atlas of iron, copper, and zinc in the mouse
cerebrum and brainstem. Analytical chemistry, 84(9),
3990-3997.
Hare, D. J., Lei, P., Ayton, S., Roberts, B. R., Grimm, R.,
George, J. L., ... & Doble, P. A. (2014). An iron–
dopamine index predicts risk of parkinsonian
neurodegeneration in the substantia nigra pars
compacta. Chemical Science, 5(6), 2160-2169.
Hare, D. J., Paul, B., & Doble, P. A. (2017). Imaging Metals
in the Brain by Laser Ablation–Inductively Coupled
Plasma-Mass Spectrometry. In Metals in the Brain (pp.
33-50). Humana Press, New York, NY.
Hare, D. J., Paul, B., & Doble, P. A. (2017). Imaging Metals
in the Brain by Laser Ablation–Inductively Coupled
Plasma-Mass Spectrometry. In Metals in the Brain (pp.
33-50). Humana Press, New York, NY.
Hare, D. J., Raven, E. P., Roberts, B. R., Bogeski, M.,
Portbury, S. D., McLean, C. A., ... & Doble, P. A. (2016).
Laser ablation-inductively coupled plasma-mass
spectrometry imaging of white and gray matter iron
distribution
in
Alzheimer's
disease
frontal
cortex. NeuroImage, 137, 124-131.
Hare, D., Reedy, B., Grimm, R., Wilkins, S., Volitakis, I.,
George, J. L., ... & Doble, P. (2009). Quantitative
elemental bio-imaging of Mn, Fe, Cu and Zn in 6hydroxydopamine induced Parkinsonism mouse
models. Metallomics, 1(1), 53-58.
Harris, E. D. (2001). Copper homeostasis: the role of
cellular transporters. Nutrition reviews, 59(9), 281-285.
Hartung, H. P., Schäfer, B., Heininger, K., & Toyka, K. V.
(1988). Suppression of experimental autoimmune neuritis
by the oxygen radical scavengers superoxide dismutase
and catalase. Annals of Neurology: Official Journal of the
American Neurological Association and the Child
Neurology Society, 23(5), 453-460.
Hartwig, C., Zlatic, S. A., Wallin, M., Vrailas-Mortimer, A.,
Fahrni, C. J., & Faundez, V. (2019). Trafficking
mechanisms
of
P-type
ATPase
copper
transporters. Current opinion in cell biology, 59, 24-33.
Hattendorf, B., Latkoczy, C., & Günther, D. (2003). Peer
reviewed: laser ablation-ICPMS.
Hentze, M. W., & Kühn, L. C. (1996). Molecular control of
vertebrate iron metabolism: mRNA-based regulatory
circuits operated by iron, nitric oxide, and oxidative
stress. Proceedings of the national academy of
sciences, 93(16), 8175-8182.
Hladky, S. B., & Barrand, M. A. (2016). Fluid and ion
transfer across the blood–brain and blood–cerebrospinal
fluid barriers; a comparative account of mechanisms and
roles. Fluids and Barriers of the CNS, 13(1), 1-69.
Howland, D. S., Liu, J., She, Y., Goad, B., Maragakis, N. J.,
Kim, B., ... & Rothstein, J. D. (2002). Focal loss of the
glutamate transporter EAAT2 in a transgenic rat model of
SOD1 mutant-mediated amyotrophic lateral sclerosis
Essential Metal detection in brain using LA-ICP-MS
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
(ALS). Proceedings of the National Academy of
Sciences, 99(3), 1604-1609.
Howland, D. S., Liu, J., She, Y., Goad, B., Maragakis, N. J.,
Kim, B., ... & Rothstein, J. D. (2002). Focal loss of the
glutamate transporter EAAT2 in a transgenic rat model of
SOD1 mutant-mediated amyotrophic lateral sclerosis
(ALS). Proceedings of the National Academy of
Sciences, 99(3), 1604-1609.
Hozumi, I., Yamada, M., Uchida, Y., Ozawa, K., Takahashi,
H., & Inuzuka, T. (2008). The expression of
metallothioneins is diminished in the spinal cords of
patients with sporadic ALS. Amyotrophic Lateral
Sclerosis, 9(5), 294-298.
Huang, L., & Tepaamorndech, S. (2013). The SLC30 family
of zinc transporters–a review of current understanding of
their biological and pathophysiological roles. Molecular
aspects of medicine, 34(2-3), 548-560.
Huang, X., Cuajungco, M. P., Atwood, C. S., Hartshorn, M.
A., Tyndall, J. D., Hanson, G. R., ... & Bush, A. I. (1999).
Cu (II) potentiation of Alzheimer Aβ neurotoxicity:
correlation with cell-free hydrogen peroxide production
and
metal
reduction. Journal
of
Biological
Chemistry, 274(52), 37111-37116.
Hulet, S. W., Hess, E. J., Debinski, W., Arosio, P., Bruce,
K., Powers, S., & Connor, J. R. (1999). Characterization
and distribution of ferritin binding sites in the adult mouse
brain. Journal of neurochemistry, 72(2), 868-874..
Hulet, S. W., Heyliger, S. O., Powers, S., & Connor, J. R.
(2000). Oligodendrocyte progenitor cells internalize
ferritin via clathrin‐dependent receptor mediated
endocytosis. Journal of neuroscience research, 61(1), 5260.
Hutchinson, R. W., Cox, A. G., McLeod, C. W., Marshall,
P. S., Harper, A., Dawson, E. L., & Howlett, D. R. (2005).
Imaging and spatial distribution of β-amyloid peptide and
metal ions in Alzheimer’s plaques by laser ablation–
inductively
coupled
plasma–mass
spectrometry. Analytical biochemistry, 346(2), 225-233.
Hwang, E. M., Kim, S. K., Sohn, J. H., Lee, J. Y., Kim, Y.,
Kim, Y. S., & Mook-Jung, I. (2006). Furin is an
endogenous regulator of α-secretase associated APP
processing. Biochemical and biophysical research
communications, 349(2), 654-659.
Ikeda, K., Hirayama, T., Takazawa, T., Kawabe, K., &
Iwasaki, Y. (2012). Relationships between disease
progression and serum levels of lipid, urate, creatinine
and ferritin in Japanese patients with amyotrophic lateral
sclerosis:
a
cross-sectional
study. Internal
medicine, 51(12), 1501-1508.
Ince, P. G., Shaw, P. J., Candy, J. M., Mantle, D., Tandon,
L., Ehmann, W. D., & Markesbery, W. R. (1994). Iron,
selenium and glutathione peroxidase activity are elevated
in sporadic motor neuron disease. Neuroscience
letters, 182(1), 87-90.
Iranmanesh, M., Iranmanesh, F., & Sadeghi, H. (2013).
Serum level of iron, zinc and copper in patients with
multiple sclerosis. Journal of Jahrom University of
Medical Sciences, 10(4), 2.
Ishigaki, S., Niwa, J. I., Ando, Y., Yoshihara, T., Sawada,
K. I., Doyu, M., ... & Sobue, G. (2002). Differentially
expressed genes in sporadic amyotrophic lateral sclerosis
spinal cords–screening by molecular indexing and
141
subsequent
cDNA
microarray
analysis. FEBS
letters, 531(2), 354-358.
Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P.,
Stachelberger, H., Ben‐Shachar, D., & Youdim, M. B. H.
(1992). Iron‐melanin complex in substantia nigra of
parkinsonian brains: an x‐ray microanalysis. Journal of
neurochemistry, 59(3), 1168-1171.
Jeong, S. Y., Rathore, K. I., Schulz, K., Ponka, P., Arosio,
P., & David, S. (2009). Dysregulation of iron homeostasis
in the CNS contributes to disease progression in a mouse
model of amyotrophic lateral sclerosis. Journal of
Neuroscience, 29(3), 610-619.
Jomova, K., & Valko, M. (2011). Advances in metalinduced
oxidative
stress
and
human
disease. Toxicology, 283(2-3), 65-87.
Jomova, K., Vondrakova, D., Lawson, M., & Valko, M.
(2010). Metals, oxidative stress and neurodegenerative
disorders. Molecular and cellular biochemistry, 345(1),
91-104.
Juneja, T., Pericak-Vance, M. A., Laing, N. G., Dave, S., &
Siddique, T. (1997). Prognosis in familial amyotrophic
lateral sclerosis: progression and survival in patients with
glu100gly and ala4val mutations in Cu, Zn superoxide
dismutase. Neurology, 48(1), 55-57.
Kambe, T., Fukue, K., Ishida, R., & Miyazaki, S. (2015).
Overview of inherited zinc deficiency in infants and
children. Journal
of
nutritional
science
and
vitaminology, 61(Supplement), S44-S46.
Kaneko, M., Noguchi, T., Ikegami, S., Sakurai, T., Kakita,
A., Toyoshima, Y., ... & Hozumi, I. (2015). Zinc
transporters ZnT3 and ZnT6 are downregulated in the
spinal cords of patients with sporadic amyotrophic lateral
sclerosis. Journal of neuroscience research, 93(2), 370379.
Kasarskis, E. J., Tandon, L., Lovell, M. A., & Ehmann, W.
D. (1995). Aluminum, calcium, and iron in the spinal cord
of patients with sporadic amyotrophic lateral sclerosis
using laser microprobe mass spectroscopy: a preliminary
study. Journal of the neurological sciences, 130(2), 203208.
Kato, S., Takikawa, M., Nakashima, K., Hirano, A.,
Cleveland, D. W., Kusaka, H., ... & Ohama, E. (2000).
New consensus research on neuropathological aspects of
familial amyotrophic lateral sclerosis with superoxide
dismutase 1 (SOD1) gene mutations: inclusions
containing SOD1 in neurons and astrocytes. Amyotrophic
Lateral Sclerosis and Other Motor Neuron
Disorders, 1(3), 163-184.
Khare, M., Singh, A. V., & Zamboni, P. (2014). Prospect of
brain machine interface in motor disabilities: the future
support for multiple sclerosis patient to improve quality
of life. Annals of medical and health sciences
research, 4(3), 305-312.
Kodama, H., Fujisawa, C., & Bhadhprasit, W. (2012).
Inherited copper transport disorders: biochemical
mechanisms, diagnosis, and treatment. Current drug
metabolism, 13(3), 237-250.
Kozlowski, H., Łuczkowski, M., & Remelli, M. (2010).
Prion proteins and copper ions. Biological and chemical
controversies. Dalton Transactions, 39(28), 6371-6385.
Kozlowski, H., Luczkowski, M., Remelli, M., & Valensin,
D. (2012). Copper, zinc and iron in neurodegenerative
diseases
(Alzheimer's,
Parkinson's
and
prion
Essential Metal detection in brain using LA-ICP-MS
142
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
diseases). Coordination Chemistry Reviews, 256(19-20),
2129-2141.
Kupershmidt, L., Weinreb, O., Amit, T., Mandel, S., Carri,
M. T., & Youdim, M. B. (2009). Neuroprotective and
neuritogenic activities of novel multimodal iron‐chelating
drugs in motor‐neuron‐like NSC‐34 cells and transgenic
mouse model of amyotrophic lateral sclerosis. The
FASEB journal, 23(11), 3766-3779.
Lee, J., Kim, C. H., Kim, D. G., & Ahn, Y. S. (2009). Zinc
Inhibits Amyloid β Production from Alzheimer's Amyloid
Precursor Protein in SH-SY5Y Cells. The Korean journal
of physiology & pharmacology: official journal of the
Korean Physiological Society and the Korean Society of
Pharmacology, 13(3), 195.
Lee, T. G., Park, J. W., Shon, H. K., Moon, D. W., Choi, W.
W., Li, K., & Chung, J. H. (2008). Biochemical imaging
of tissues by SIMS for biomedical applications. Applied
Surface Science, 255(4), 1241-1248.
Leskovjan, A. C., Kretlow, A., Lanzirotti, A., Barrea, R.,
Vogt, S., & Miller, L. M. (2011). Increased brain iron
coincides with early plaque formation in a mouse model
of Alzheimer's disease. Neuroimage, 55(1), 32-38.
Leskovjan, A. C., Lanzirotti, A., & Miller, L. M. (2009).
Amyloid plaques in PSAPP mice bind less metal than
plaques
in
human
Alzheimer's
disease. NeuroImage, 47(4), 1215-1220.
Leveugle, B., Faucheux, B. A., Bouras, C., Nillesse, N.,
Spik, G., Hirsch, E. C., ... & Hof, P. R. (1996). Cellular
distribution of the iron-binding protein lactotransferrin in
the mesencephalon of Parkinson’s disease cases. Acta
neuropathologica, 91(6), 566-572..
LeVine, S. M. (1997). Iron deposits in multiple sclerosis and
Alzheimer's disease brains. Brain research, 760(1-2),
298-303.
Li Y, Jiao Q, Xu H, Du X, Shi L, Jia F, Jiang H (2017)
Biometal dyshomeostasis and toxic metal accumulations
in the development of Alzheimer’s disease. Frontiers in
molecular neuroscience 10:339.
Li, K., & Reichmann, H. (2016). Role of iron in
neurodegenerative
diseases. Journal
of
Neural
Transmission, 123(4), 389-399.
Linder, M. C., & Hazegh-Azam, M. (1996). Copper
biochemistry and molecular biology. The American
journal of clinical nutrition, 63(5), 797S-811S.
Ling, Y., Morgan, K., & Kalsheker, N. (2003). Amyloid
precursor protein (APP) and the biology of proteolytic
processing: relevance to Alzheimer’s disease. The
international journal of biochemistry & cell
biology, 35(11), 1505-1535.
Llanos, R. M., & Mercer, J. F. (2002). The molecular basis
of copper homeostasis copper-related disorders. DNA
and cell biology, 21(4), 259-270.
Localization of copper and copper transporters in the human
brain. Metallomics 5(1):43-51.
Loeffler, D. A., Connor, J. R., Juneau, P. L., Snyder, B. S.,
Kanaley, L., DeMaggio, A. J., ... & LeWitt, P. A. (1995).
Transferrin and iron in normal, Alzheimer's disease, and
Parkinson's
disease
brain
regions. Journal
of
neurochemistry, 65(2), 710-716.
Logroscino, G., Marder, K., Graziano, J., Freyer, G.,
Slavkovich, V., LoIacono, N., ... & Mayeux, R. (1997).
Altered systemic iron metabolism in Parkinson's
disease. Neurology, 49(3), 714-717.
Lohrke, J., Frisk, A. L., Frenzel, T., Schöckel, L.,
Rosenbruch, M., Jost, G., ... & Pietsch, H. (2017).
Histology and gadolinium distribution in the rodent brain
after the administration of cumulative high doses of linear
and
macrocyclic
gadolinium-based
contrast
agents. Investigative radiology, 52(6), 324.
Lovell, M. A., Xiong, S., Xie, C., Davies, P., & Markesbery,
W. R. (2004). Induction of hyperphosphorylated tau in
primary rat cortical neuron cultures mediated by oxidative
stress and glycogen synthase kinase-3. Journal of
Alzheimer's Disease, 6(6), 659-671.
Lyons, T. J., Liu, H., Goto, J. J., Nersissian, A., Roe, J. A.,
Graden, J. A., ... & Valentine, J. S. (1996). Mutations in
copper-zinc superoxide dismutase that cause amyotrophic
lateral sclerosis alter the zinc binding site and the redox
behavior of the protein. Proceedings of the National
Academy of Sciences, 93(22), 12240-12244.
Macreadie, I. G. (2008). Copper transport and Alzheimer’s
disease. European Biophysics Journal, 37(3), 295-300.
Madsen, E., & Gitlin, J. D. (2007). Copper and iron
disorders of the brain. Annu. Rev. Neurosci., 30, 317337.
Majumdar, S., Peralta-Videa, J. R., Castillo-Michel, H.,
Hong, J., Rico, C. M., & Gardea-Torresdey, J. L. (2012).
Applications of synchrotron μ-XRF to study the
distribution of biologically important elements in
different environmental matrices: A review. Analytica
chimica acta, 755, 1-16.
Marchetti, C. (2003). Molecular targets of lead in brain
neurotoxicity. Neurotoxicity research, 5(3), 221-235.
Markesbery, W. R., Ehmann, W. D., Candy, J. M., Ince, P.
G., Shaw, P. J., Tandon, L., & Deibel, M. A. (1995).
Neutron activation analysis of trace elements in motor
neuron disease spinal cord. Neurodegeneration, 4(4),
383-390.
Martin, L. J., Price, A. C., Kaiser, A., Shaikh, A. Y., & Liu,
Z. (2000). Mechanisms for neuronal degeneration in
amyotrophic lateral sclerosis and in models of motor
neuron death. International journal of molecular
medicine, 5(1), 3-16.
Masaldan, S., Clatworthy, S. A., Gamell, C., Meggyesy, P.
M., Rigopoulos, A. T., Haupt, S., ... & Cater, M. A.
(2018). Iron accumulation in senescent cells is coupled
with impaired ferritinophagy and inhibition of
ferroptosis. Redox biology, 14, 100-115.
Matusch, A., Depboylu, C., Palm, C., Wu, B., Höglinger, G.
U., Schäfer, M. K. H., & Becker, J. S. (2010). Cerebral
bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse
model of Parkinson’s disease using laser ablation
inductively coupled plasma mass spectrometry (LA-ICPMS). Journal of the American Society for Mass
Spectrometry, 21(1), 161-171.
Maywald, M., Wessels, I., & Rink, L. (2017). Zinc signals
and immunity. International journal of molecular
sciences, 18(10), 2222.
Medici, V., & Huster, D. (2017). Animal models of Wilson
disease. Handbook of clinical neurology, 142, 57-70.
Meloni, G., Faller, P., & Vaša, M. (2007). Redox silencing
of copper in metal-linked neurodegenerative disorders:
reaction of Zn7metallothionein-3 with Cu2+ ions. Journal
of Biological Chemistry, 282(22), 16068-16078.
Essential Metal detection in brain using LA-ICP-MS
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
Mercer, J. F. (2001). The molecular basis of coppertransport diseases. Trends in molecular medicine, 7(2),
64-69.
Merle, U., & Weiskirchen, R. (2016). Wilson's disease: an
inherited, silent, copper intoxication disease. Emj
Neurol, 4, 74-83.
Miyazaki, I., & Asanuma, M. (2008). Dopaminergic
neuron-specific oxidative stress caused by dopamine
itself. Acta Medica Okayama, 62(3), 141-150.
Mo, Z. Y., Zhu, Y. Z., Zhu, H. L., Fan, J. B., Chen, J., &
Liang, Y. (2009). Low micromolar zinc accelerates the
fibrillization of human tau via bridging of Cys-291 and
Cys-322. Journal of Biological Chemistry, 284(50),
34648-34657.
Mokgalaka, N. S., & Gardea‐Torresdey, J. L. (2006). Laser
ablation inductively coupled plasma mass spectrometry:
Principles and applications. Applied Spectroscopy
Reviews, 41(2), 131-150.
Münch, G., Lüth, H. J., Wong, A., Arendt, T., Hirsch, E.,
Ravid, R. A., & Riederer, P. (2000). Crosslinking of αsynuclein by advanced glycation endproducts—an early
pathophysiological
step
in
Lewy
body
formation?. Journal of chemical neuroanatomy, 20(3-4),
253-257.
Nadal, R. C., Davies, P., Brown, D. R., & Viles, J. H.
(2009). Evaluation of copper2+ affinities for the prion
protein. Biochemistry, 48(38), 8929-8931.
Nadjar, Y., Gordon, P., Corcia, P., Bensimon, G., Pieroni,
L., Meininger, V., & Salachas, F. (2012). Elevated serum
ferritin is associated with reduced survival in amyotrophic
lateral sclerosis. PloS one, 7(9), e45034.
Nagano, S., Satoh, M., Sumi, H., Fujimura, H., Tohyama,
C., Yanagihara, T., & Sakoda, S. (2001). Reduction of
metallothioneins promotes the disease expression of
familial amyotrophic lateral sclerosis mice in a dose‐
dependent
manner. European
Journal
of
Neuroscience, 13(7), 1363-1370.
Nakashima, K., Watanabe, Y., Kuno, N., Nanba, E., &
Takahashi, K. (1995). Abnormality of Can superoxide
dismutase (SOD1) activity in Japanese familial
amyotrophic lateral sclerosis with two base pair deletion
in the SODl gene. Neurology, 45(5), 1019-1019.
Nishihara, E., Furuyama, T., Yamashita, S., & Mori, N.
(1998). Expression of copper trafficking genes in the
mouse brain. Neuroreport, 9(14), 3259-3263.
Nishimura, N., Nishimura, H., Ghaffar, A., & Tohyama, C.
(1992). Localization of metallothionein in the brain of rat
and
mouse. Journal
of
Histochemistry
&
Cytochemistry, 40(2), 309-315.
Noy, D., Solomonov, I., Sinkevich, O., Arad, T., Kjaer, K.,
& Sagi, I. (2008). Zinc-amyloid β interactions on a
millisecond time-scale stabilize non-fibrillar Alzheimerrelated species. Journal of the American Chemical
Society, 130(4), 1376-1383.
Paik, S. R., SHIN, H. J., LEE, J. H., CHANG, C. S., & KIM,
J. (1999). Copper (II)-induced self-oligomerization of αsynuclein. Biochemical Journal, 340(3), 821-828.
Pánik, J., Kopáni, M., Zeman, J., Ješkovský, M., Kaizer, J.,
& Povinec, P. P. (2018). Determination of metal elements
concentrations in human brain tissues using PIXE and
EDX methods. Journal of Radioanalytical and Nuclear
Chemistry, 318(3), 2313-2319.
143
Parthasarathy, S., Yoo, B., McElheny, D., Tay, W., & Ishii,
Y. (2014). Capturing a reactive state of amyloid
aggregates. Journal of Biological Chemistry, 289(14),
9998-10010.
Pei, J. J., An, W. L., Zhou, X. W., Nishimura, T., Norberg,
J., Benedikz, E., ... & Winblad, B. (2006). P70 S6 kinase
mediates tau phosphorylation and synthesis. FEBS
letters, 580(1), 107-114.
Pichler, R., Dunzinger, A., Wurm, G., Pichler, J., Weis, S.,
Nußbaumer, K., ... & Aigner, R. M. (2010). Is there a
place for FET PET in the initial evaluation of brain lesions
with unknown significance?. European journal of nuclear
medicine and molecular imaging, 37(8), 1521-1528.
Pickhardt, C., Izmer, A. V., Zoriy, M. V., Schaumlöffel, D.,
& Becker, J. S. (2006). On-line isotope dilution in laser
ablation inductively coupled plasma mass spectrometry
using a microflow nebulizer inserted in the laser ablation
chamber. International
Journal
of
Mass
Spectrometry, 248(3), 136-141.
Pierson, J., Norris, J. L., Aerni, H. R., Svenningsson, P.,
Caprioli, R. M., & Andrén, P. E. (2004). Molecular
profiling of experimental Parkinson's disease: direct
analysis of peptides and proteins on brain tissue sections
by MALDI mass spectrometry. Journal of proteome
research, 3(2), 289-295.
Pohl, H. R., Roney, N., & Abadin, H. G. (2015). 10 Metal
Ions Affecting the Neurological System. In Metal Ions in
Toxicology: Effects, Interactions, Interdependencies (pp.
247-262). De Gruyter.
Polishchuk, E. V., Merolla, A., Lichtmannegger, J.,
Romano, A., Indrieri, A., Ilyechova, E. Y., ... &
Polishchuk, R. S. (2019). Activation of autophagy,
observed in liver tissues from patients with Wilson
disease and from ATP7B-deficient animals, protects
hepatocytes
from
copper-induced
apoptosis. Gastroenterology, 156(4), 1173-1189.
Popescu, B. F. G., George, M. J., Bergmann, U.,
Garachtchenko, A. V., Kelly, M. E., McCrea, R. P., ... &
Nichol, H. (2009). Mapping metals in Parkinson's and
normal
brain
using
rapid-scanning
x-ray
fluorescence. Physics in Medicine & Biology, 54(3), 651.
Portbury, S. D., & Adlard, P. A. (2017). Zinc signal in brain
diseases. International
journal
of
molecular
sciences, 18(12), 2506.
Portbury, S. D., Hare, D. J., Sgambelloni, C., Finkelstein, D.
I., & Adlard, P. A. (2016). A time-course analysis of
changes in cerebral metal levels following a controlled
cortical impact. Metallomics, 8(2), 193-200.
Potter, D. (2008). A commercial perspective on the growth
and development of the quadrupole ICP-MS
market. Journal
of
Analytical
Atomic
Spectrometry, 23(5), 690-693.
Prashanth, L., Kattapagari, K. K., Chitturi, R. T., Baddam,
V. R. R., & Prasad, L. K. (2015). A review on role of
essential trace elements in health and disease. Journal of
dr. ntr university of health sciences, 4(2), 75.
Puttaparthi, K., Gitomer, W. L., Krishnan, U., Son, M.,
Rajendran, B., & Elliott, J. L. (2002). Disease progression
in a transgenic model of familial amyotrophic lateral
sclerosis is dependent on both neuronal and non-neuronal
zinc binding proteins. Journal of Neuroscience, 22(20),
8790-8796.
Essential Metal detection in brain using LA-ICP-MS
144
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
Puttaparthi, K., Wojcik, C., Rajendran, B., DeMartino, G.
N., & Elliott, J. L. (2003). Aggregate formation in the
spinal cord of mutant SOD1 transgenic mice is reversible
and
mediated
by
proteasomes. Journal
of
neurochemistry, 87(4), 851-860.
Quaife, C. J., Findley, S. D., Erickson, J. C., Froelick, G. J.,
Kelly, E. J., Zambrowicz, B. P., & Palmiter, R. D. (1994).
Induction of a new metallothionein isoform (MT-IV)
occurs during differentiation of stratified squamous
epithelia. Biochemistry, 33(23), 7250-7259.
Que, E. L., Domaille, D. W., & Chang, C. J. (2008). Metals
in neurobiology: probing their chemistry and biology with
molecular imaging. Chemical reviews, 108(5), 15171549.
Rangarajan, S., & D’Souza, G. A. (2007). Restless legs
syndrome in Indian patients having iron deficiency
anemia in a tertiary care hospital. Sleep medicine, 8(3),
247-251.
Raymond, M. J., Ray, P., Kaur, G., Fredericks, M., Singh,
A. V., & Wan, L. Q. (2017). Multiaxial polarity
determines
individual
cellular
and
nuclear
chirality. Cellular and molecular bioengineering, 10(1),
63-74.
Regland, B., Lehmann, W., Abedini, I., Blennow, K.,
Jonsson, M., Karlsson, I., ... & Gottfries, C. G. (2001).
Treatment
of
Alzheimer’s
disease
with
clioquinol. Dementia
and
geriatric
cognitive
disorders, 12(6), 408-414.
Rinne, J. O., Portin, R., Ruottinen, H., Nurmi, E., Bergman,
J., Haaparanta, M., & Solin, O. (2000). Cognitive
impairment and the brain dopaminergic system in
Parkinson disease:[18F] fluorodopa positron emission
tomographic study. Archives of neurology, 57(4), 470475.
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S.,
Mastwyk, M., MacGregor, L., ... & Masters, C. L. (2003).
Metal-protein attenuation with iodochlorhydroxyquin
(clioquinol) targeting Aβ amyloid deposition and toxicity
in Alzheimer disease: a pilot phase 2 clinical
trial. Archives of neurology, 60(12), 1685-1691.
Roberts, B. R., Lim, N. K., McAllum, E. J., Donnelly, P. S.,
Hare, D. J., Doble, P. A., ... & Crouch, P. J. (2014). Oral
treatment with CuII (atsm) increases mutant SOD1 in
vivo but protects motor neurons and improves the
phenotype of a transgenic mouse model of amyotrophic
lateral sclerosis. Journal of Neuroscience, 34(23), 80218031.
Roberts, B. R., Tainer, J. A., Getzoff, E. D., Malencik, D.
A., Anderson, S. R., Bomben, V. C., ... & Beckman, J. S.
(2007). Structural characterization of zinc-deficient
human superoxide dismutase and implications for
ALS. Journal of molecular biology, 373(4), 877-890.
Rogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S.,
Huang, X., Gunshin, H., ... & Gullans, S. R. (2002). An
iron-responsive element type II in the 5′-untranslated
region of the Alzheimer's amyloid precursor protein
transcript. Journal of Biological Chemistry, 277(47),
45518-45528.
Roskams, A. J., & Connor, J. R. (1990). Aluminum access
to the brain: a role for transferrin and its
receptor. Proceedings of the National Academy of
Sciences, 87(22), 9024-9027.
Rossi, M., Ruottinen, H., Soimakallio, S., Elovaara, I., &
Dastidar, P. (2013). Clinical MRI for iron detection in
Parkinson's disease. Clinical imaging, 37(4), 631-636.
Rowland, L. P., & Shneider, N. A. (2001). Amyotrophic
lateral
sclerosis. New
England
Journal
of
Medicine, 344(22), 1688-1700.
Sabine Becker, J., Matusch, A., Palm, C., Salber, D.,
Morton, K. A., & Susanne Becker, J. (2010). Bioimaging
of metals in brain tissue by laser ablation inductively
coupled plasma mass spectrometry (LA-ICP-MS) and
metallomics. Metallomics, 2(2), 104-111.
Saeed, M., Khan, H., Khan, M. A., Khan, F., Khan, S. A., &
Muhammad, N. (2010). Quantification of various metals
and cytotoxic profile of aerial parts of Polygonatum
verticillatum. Pak. J. Bot, 42(6), 3995-4002.
Saini, N., & Schaffner, W. (2010). Zinc supplement greatly
improves
the
condition
of
parkin
mutant
Drosophila. Biological chemistry, 391(5), 513-518.
Salber D, Stoffels G, Pauleit D, Oros-Peusquens AM, Shah
NJ, Klauth P, Hamacher K, Coenen HH, Langen KJ
(2007) Differential uptake of O-(2-18F-fluoroethyl)-Ltyrosine, L-3H-methionine, and 3H-deoxyglucose in
brain abscesses. Journal of Nuclear Medicine
48(12):2056-2062.
Scheiber, I. F., & Dringen, R. (2013). Astrocyte functions in
the copper homeostasis of the brain. Neurochemistry
international, 62(5), 556-565.
Scheiber, I. F., Mercer, J. F., & Dringen, R. (2014).
Metabolism and functions of copper in brain. Progress in
neurobiology, 116, 33-57.
Sela, H., Cohen, H., Karpas, Z., & Zeiri, Y. (2017).
Distinctive hippocampal zinc distribution patterns
following stress exposure in an animal model of
PTSD. Metallomics, 9(3), 323-333.
Sensi, S. L., Paoletti, P., Bush, A. I., & Sekler, I. (2009).
Zinc in the physiology and pathology of the CNS. Nature
reviews neuroscience, 10(11), 780-791.
Sensi, S. L., Rapposelli, I. G., Frazzini, V., & Mascetra, N.
(2008). Altered oxidant-mediated intraneuronal zinc
mobilization in a triple transgenic mouse model of
Alzheimer’s disease. Experimental gerontology, 43(5),
488-492.
Sensi, S. L., Ton-That, D., Sullivan, P. G., Jonas, E. A., Gee,
K. R., Kaczmarek, L. K., & Weiss, J. H. (2003).
Modulation of mitochondrial function by endogenous
Zn2+ pools. Proceedings of the National Academy of
Sciences, 100(10), 6157-6162.
Seuma, J., Bunch, J., Cox, A., McLeod, C., Bell, J., &
Murray,
C.
(2008).
Combination
of
immunohistochemistry and laser ablation ICP mass
spectrometry
for
imaging
of
cancer
biomarkers. Proteomics, 8(18), 3775-3784.
Sheykhansari, S., Kozielski, K., Bill, J., Sitti, M., Gemmati,
D., Zamboni, P., & Singh, A. V. (2018). Redox metals
homeostasis in multiple sclerosis and amyotrophic lateral
sclerosis: a review. Cell death & disease, 9(3), 1-16.
Shibata, N. (2001). Transgenic mouse model for familial
amyotrophic lateral sclerosis with superoxide dismutase‐
1 mutation. Neuropathology, 21(1), 82-92.
Shibata, N., Hirano, A., Yamamoto, T., Kato, Y., &
Kobayashi, M. (2000). Superoxide dismutase-1 mutationrelated neurotoxicity in familial amyotrophic lateral
Essential Metal detection in brain using LA-ICP-MS
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
sclerosis. Amyotrophic Lateral Sclerosis and Other Motor
Neuron Disorders, 1(3), 143-161.
Shibata, N., Kobayashi, M., Hirano, A., Asayama, K.,
Horiuchi, S., Dal Canto, M. C., & Gurney, M. E. (1999).
Morphological aspects of superoxide dismutase-1
mutation in amyotrophic lateral sclerosis and its
transgenic mouse model. Acta histochemica et
cytochemica, 32(1), 17-30.
Sian‐Hülsmann, J., Mandel, S., Youdim, M. B., & Riederer,
P. (2011). The relevance of iron in the pathogenesis of
Parkinson’s disease. Journal of neurochemistry, 118(6),
939-957.
Silvestri, L., & Camaschella, C. (2008). A potential
pathogenetic role of iron in Alzheimer's disease. Journal
of cellular and molecular medicine, 12(5a), 1548-1550.
Singh, A. V., Subhashree, L., Milani, P., Gemmati, D., &
Zamboni, P. (2010). Interplay of iron metallobiology,
metalloproteinases, and FXIII, and role of their gene
variants in venous leg ulcer. The international journal of
lower extremity wounds, 9(4), 166-179.
Smart, T. G., Hosie, A. M., & Miller, P. S. (2004). Zn2+
ions: modulators of excitatory and inhibitory synaptic
activity. The Neuroscientist, 10(5), 432-442.
Smith, C. D., Chebrolu, H., Wekstein, D. R., Schmitt, F. A.,
Jicha, G. A., Cooper, G., & Markesbery, W. R. (2007).
Brain structural alterations before mild cognitive
impairment. Neurology, 68(16), 1268-1273.
Squitti, R. (2012). Copper dysfunction in Alzheimer's
disease: from meta-analysis of biochemical studies to new
insight into genetics. Journal of Trace Elements in
Medicine and Biology, 26(2-3), 93-96.
Squitti, R., Polimanti, R., Siotto, M., Bucossi, S., Ventriglia,
M., Mariani, S., ... & Rossini, P. M. (2013). ATP7B
variants as modulators of copper dyshomeostasis in
Alzheimer’s disease. Neuromolecular medicine, 15(3),
515-522.
Stöckel, J., Safar, J., Wallace, A. C., Cohen, F. E., &
Prusiner, S. B. (1998). Prion protein selectively binds
copper (II) ions. Biochemistry, 37(20), 7185-7193.
Sträter, E., Westbeld, A., & Klemm, O. (2010). Pollution in
coastal
fog
at
Alto
Patache,
northern
Chile. Environmental
Science
and
Pollution
Research, 17(9), 1563-1573.
Strausak, D., Mercer, J. F., Dieter, H. H., Stremmel, W., &
Multhaup, G. (2001). Copper in disorders with
neurological symptoms: Alzheimer’s, Menkes, and
Wilson diseases. Brain research bulletin, 55(2), 175-185.
Strazielle, N., & Ghersi-Egea, J. F. (2013). Physiology of
blood–brain interfaces in relation to brain disposition of
small compounds and macromolecules. Molecular
pharmaceutics, 10(5), 1473-1491.
Sun, X. Y., Wei, Y. P., Xiong, Y., Wang, X. C., Xie, A. J.,
Wang, X. L., ... & Wang, J. Z. (2012). Synaptic released
zinc promotes tau hyperphosphorylation by inhibition of
protein phosphatase 2A (PP2A). Journal of Biological
Chemistry, 287(14), 11174-11182.
Sussulini, A., & Becker, J. S. (2015). Application of laser
microdissection ICP–MS for high resolution elemental
mapping in mouse brain tissue: A comparative study with
laser ablation ICP–MS. Talanta, 132, 579-582.
Szewczyk,
B.
(2013).
Zinc
homeostasis
and
neurodegenerative
disorders. Frontiers
in
aging
neuroscience, 5, 33.
145
Takeda, A. (2000). Movement of zinc and its functional
significance in the brain. Brain research reviews, 34(3),
137-148.
Takeda, A. (2004). Essential trace metals and brain
function. JOURNAL-PHARMACEUTICAL SOCIETY
OF JAPAN, 124(9), 577-586.
Taylor, E. M., & Morgan, E. H. (1990). Developmental
changes in transferrin and iron uptake by the brain in the
rat. Developmental Brain Research, 55(1), 35-42.
Tchounwou, P. B., Yedjou, C. G., Patlolla, A. K., & Sutton,
D. J. (2012). Heavy metal toxicity and the
environment. Molecular, clinical and environmental
toxicology, 133-164.
Thakur, A. K., Srivastava, A. K., Srinivas, V., Chary, K. V.
R., & Rao, C. M. (2011). Copper alters aggregation
behavior of prion protein and induces novel interactions
between its N-and C-terminal regions. Journal of
Biological Chemistry, 286(44), 38533-38545.
Tokuda, E., & Furukawa, Y. (2016). Copper homeostasis as
a therapeutic target in amyotrophic lateral sclerosis with
SOD1 mutations. International journal of molecular
sciences, 17(5), 636.
Tórsdóttir, G., Kristinsson, J., Sveinbjörnsdóttir, S.,
Snaedal, J., & Jóhannesson, T. (1999). Copper,
ceruloplasmin, superoxide dismutase and iron parameters
in Parkinson's disease. Pharmacology & toxicology, 85,
239-243.
Tórsdóttir, G., Kristinsson, J., Sveinbjörnsdóttir, S.,
Snaedal, J., & Jóhannesson, T. (1999). Copper,
ceruloplasmin, superoxide dismutase and iron parameters
in Parkinson's disease. Pharmacology & toxicology, 85,
239-243.
Tümer, Z. (2013). An overview and update of ATP7A
mutations leading to Menkes disease and occipital horn
syndrome. Human mutation, 34(3), 417-429.
Uttara, B., Singh, A. V., Zamboni, P., & Mahajan, R. T.
(2009). Oxidative stress and neurodegenerative diseases:
a review of upstream and downstream antioxidant
therapeutic options. Current neuropharmacology, 7(1),
65-74.
Uversky, V. N., Li, J., & Fink, A. L. (2001). Metal-triggered
Structural Transformations, Aggregation, and Fibrillation
of Human α-Synuclein: A Possible Molecular Link
between Parkinson′ s Disease and Heavy Metal
Exposure. Journal of Biological Chemistry, 276(47),
44284-44296.
Valentine JS, Doucette PA, Zittin Potter S (2005) Copperzinc superoxide dismutase and amyotrophic lateral
sclerosis. Annu. Rev. Biochem 74:563-593.
Veasey, S. C., Lear, J., Zhu, Y., Grinspan, J. B., Hare, D. J.,
Wang, S., ... & Robinson, S. R. (2013). Long-term
intermittent hypoxia elevates cobalt levels in the brain and
injures white matter in adult mice. Sleep, 36(10), 14711481.
Veyrat-Durebex, C., Corcia, P., Mucha, A., Benzimra, S.,
Mallet, C., Gendrot, C., ... & Blasco, H. (2014). Iron
metabolism disturbance in a French cohort of ALS
patients. BioMed research international, 2014.
Vickerman, J., & Winograd, N. (2013). Cluster TOF-SIMS
imaging and the characterization of biological
materials. Cluster Secondary Ion Mass Spectrometry,
269-312.
Essential Metal detection in brain using LA-ICP-MS
146
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
Visconti, A., Cotichini, R., Cannoni, S., Bocca, B., Forte,
G., Ghazaryan, A., ... & Ristori, G. (2005). Concentration
of elements in serum of patients affected by multiple
sclerosis with first demyelinating episode: a six-month
longitudinal follow-up study. Annali dell'Istituto
superiore di sanita, 41(2), 217-222.
Vulpe, C., Levinson, B., Whitney, S., Packman, S., &
Gitschier, J. (1993). Isolation of a candidate gene for
Menkes disease and evidence that it encodes a copper–
transporting ATPase. Nature genetics, 3(1), 7-13.
Waggoner, D. J., Bartnikas, T. B., & Gitlin, J. D. (1999).
The
role
of
copper
in
neurodegenerative
disease. Neurobiology of disease, 6(4), 221-230.
Wallis, L. I., Paley, M. N., Graham, J. M., Grünewald, R.
A., Wignall, E. L., Joy, H. M., & Griffiths, P. D. (2008).
MRI assessment of basal ganglia iron deposition in
Parkinson's disease. Journal of Magnetic Resonance
Imaging: An Official Journal of the International Society
for Magnetic Resonance in Medicine, 28(5), 1061-1067.
Walter, E. D., Stevens, D. J., Spevacek, A. R., Visconte, M.
P., Rossi, A. D., & Millhauser, G. L. (2009). Copper
binding extrinsic to the octarepeat region in the prion
protein. Current Protein and Peptide Science, 10(5), 529535.
Wan, L., Nie, G., Zhang, J., Luo, Y., Zhang, P., Zhang, Z.,
& Zhao, B. (2011). β-Amyloid peptide increases levels of
iron content and oxidative stress in human cell and
Caenorhabditis elegans models of Alzheimer
disease. Free Radical Biology and Medicine, 50(1), 122129.
Wang, J., Zhang, Y., Tang, L., Zhang, N., & Fan, D. (2011).
Protective effects of resveratrol through the up-regulation
of SIRT1 expression in the mutant hSOD1-G93A-bearing
motor neuron-like cell culture model of amyotrophic
lateral sclerosis. Neuroscience letters, 503(3), 250-255.
Wang, L. M., Becker, J. S., Wu, Q., Oliveira, M. F., Bozza,
F. A., Schwager, A. L., ... & Morton, K. A. (2010).
Bioimaging of copper alterations in the aging mouse brain
by autoradiography, laser ablation inductively coupled
plasma
mass
spectrometry
and
immunohistochemistry. Metallomics, 2(5), 348-353.
Wang, X. S., Lee, S., Simmons, Z., Boyer, P., Scott, K., Liu,
W., & Connor, J. (2004). Increased incidence of the Hfe
mutation in amyotrophic lateral sclerosis and related
cellular consequences. Journal of the neurological
sciences, 227(1), 27-33.
Wang, X., Moualla, D., Wright, J. A., & Brown, D. R.
(2010). Copper binding regulates intracellular alpha‐
synuclein localisation, aggregation and toxicity. Journal
of neurochemistry, 113(3), 704-714.
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., &
Zecca, L. (2014). The role of iron in brain ageing and
neurodegenerative
disorders. The
Lancet
Neurology, 13(10), 1045-1060.
Weinreb, O., Amit, T., Mandel, S., Kupershmidt, L., &
Youdim, M. B. (2010). Neuroprotective multifunctional
iron chelators: from redox-sensitive process to novel
therapeutic opportunities. Antioxidants
& redox
signaling, 13(6), 919-949.
Weiskirchen, S., Kim, P., & Weiskirchen, R. (2019). Laser
Ablation Inductively Coupled Plasma Spectrometry:
Metal Imaging in Experimental and Clinical Wilson
Disease. Inorganics, 7(4), 54.
Wijesekera, L. C., & Leigh, P. N. (2009). Amyotrophic
lateral sclerosis. Orphanet journal of rare diseases, 4(1),
1-22.
Wilms, H., Rosenstiel, P., Sievers, J., Deuschl, G., Zecca,
L., & Lucius, R. (2003). Activation of microglia by
human neuromelanin is NF‐κB‐dependent and involves
p38 mitogen‐activated protein kinase: implications for
Parkinson's disease. The FASEB journal, 17(3), 1-20.
Wilquet, V., & De Strooper, B. (2004). Amyloid-beta
precursor
protein
processing
in
neurodegeneration. Current
opinion
in
neurobiology, 14(5), 582-588.
Wind, M., Feldmann, I., Jakubowski, N., & Lehmann, W.
D. (2003). Spotting and quantification of phosphoproteins
purified by gel electrophoresis and laser ablation‐element
mass
spectrometry
with
phosphorus‐31
detection. Electrophoresis, 24(7‐8), 1276-1280.
Winkler, E. A., Sengillo, J. D., Sagare, A. P., Zhao, Z., Ma,
Q., Zuniga, E., ... & Zlokovic, B. V. (2014). Blood–spinal
cord barrier disruption contributes to early motor-neuron
degeneration in ALS-model mice. Proceedings of the
National Academy of Sciences, 111(11), E1035-E1042.
Wong, C. P., Magnusson, K. R., & Ho, E. (2013). Increased
inflammatory response in aged mice is associated with
age-related zinc deficiency and zinc transporter
dysregulation. The
Journal
of
nutritional
biochemistry, 24(1), 353-359.
Wright, J. A., Wang, X., & Brown, D. R. (2009). Unique
copper‐induced oligomers mediate alpha‐synuclein
toxicity. The FASEB Journal, 23(8), 2384-2393.
Wu, B., Niehren, S., & Becker, J. S. (2011). Mass
spectrometric imaging of elements in biological tissues by
new BrainMet technique—laser microdissection
inductively coupled plasma mass spectrometry (LMDICP-MS). Journal
of
analytical
atomic
spectrometry, 26(8), 1653-1659.
Xu, N., Majidi, V., Ehmann, W. D., & Markesbery, W. R.
(1992). Determination of aluminium in human brain
tissue
by
electrothermal
atomic
absorption
spectrometry. Journal
of
Analytical
Atomic
Spectrometry, 7(5), 749-751.
Yager, J. Y., & Hartfield, D. S. (2002). Neurologic
manifestations of iron deficiency in childhood. Pediatric
neurology, 27(2), 85-92.
Yamamoto, A., Shin, R. W., Hasegawa, K., Naiki, H., Sato,
H., Yoshimasu, F., & Kitamoto, T. (2002). Iron (III)
induces aggregation of hyperphosphorylated τ and its
reduction to iron (II) reverses the aggregation:
implications in the formation of neurofibrillary tangles of
Alzheimer's disease. Journal of neurochemistry, 82(5),
1137-1147.
Yasui, M., Ota, K., & Garruto, R. M. (1993). Concentrations
of zinc and iron in the brains of Guamanian patients with
amyotrophic lateral sclerosis and parkinsonismdementia. Neurotoxicology, 14(4), 445-450.
Yegambaram, M., Manivannan, B., G Beach, T., & U
Halden, R. (2015). Role of environmental contaminants
in the etiology of Alzheimer’s disease: a review. Current
Alzheimer Research, 12(2), 116-146.
Yoshida, M., Takahashi, Y., Koike, A., Fukuda, Y., Goto,
J., & Tsuji, S. (2010). A mutation database for
amyotrophic lateral sclerosis. Human mutation, 31(9),
1003-1010.
Essential Metal detection in brain using LA-ICP-MS
Niger. J. Physiol. Sci. 36 (2021): Folarin et. al.
Youdim, M. B. (1990). Neuropharmacological and
neurobiochemical aspects of iron deficiency. In Brain,
behaviour, and iron in the infant diet (pp. 83-99).
Springer, London.
Yu, W. H., Lukiw, W. J., Bergeron, C., Niznik, H. B., &
Fraser, P. E. (2001). Metallothionein III is reduced in
Alzheimer’s disease. Brain research, 894(1), 37-45.
Zamboni, P., Tognazzo, S., Izzo, M., Pancaldi, F., Scapoli,
G. L., Liboni, A., & Gemmati, D. (2005).
Hemochromatosis C282Y gene mutation increases the
risk of venous leg ulceration. Journal of vascular
surgery, 42(2), 309-314.
Zecca, L., Fariello, R., Riederer, P., Sulzer, D., Gatti, A., &
Tampellini, D. (2002). The absolute concentration of
nigral neuromelanin, assayed by a new sensitive method,
increases throughout the life and is dramatically
decreased in Parkinson's disease. FEBS letters, 510(3),
216-220.
Zecca, L., Shima, T., Stroppolo, A., Goj, C., Battiston, G.
A., Gerbasi, R., ... & Swartz, H. M. (1996). Interaction of
neuromelanin and iron in substantia nigra and other areas
of human brain. Neuroscience, 73(2), 407-415.
Zecca, L., Youdim, M. B., Riederer, P., Connor, J. R., &
Crichton, R. R. (2004). Iron, brain ageing and
147
neurodegenerative
disorders. Nature
Reviews
Neuroscience, 5(11), 863-873.
Zheng, W., & Monnot, A. D. (2012). Regulation of brain
iron and copper homeostasis by brain barrier systems:
implication in neurodegenerative diseases. Pharmacology
& therapeutics, 133(2), 177-188.
Zoriy, M. V., Dehnhardt, M., Reifenberger, G., Zilles, K., &
Becker, J. S. (2006). Imaging of Cu, Zn, Pb and U in
human brain tumor resections by laser ablation
inductively
coupled
plasma
mass
spectrometry. International
Journal
of
Mass
Spectrometry, 257(1-3), 27-33.
Zoriy, M., Matusch, A., Spruss, T., & Becker, J. S. (2007).
Laser ablation inductively coupled plasma mass
spectrometry for imaging of copper, zinc, and platinum in
thin sections of a kidney from a mouse treated with cisplatin. International
Journal
of
Mass
Spectrometry, 260(2-3), 102-106.
Zucca, F. A., Basso, E., Cupaioli, F. A., Ferrari, E., Sulzer,
D., Casella, L., & Zecca, L. (2014). Neuromelanin of the
human substantia nigra: an update. Neurotoxicity
research, 25(1), 13-23.
Essential Metal detection in brain using LA-ICP-MS